NZ516896A - Ascididemin derivatives and their therapeutic applications - Google Patents

Ascididemin derivatives and their therapeutic applications

Info

Publication number
NZ516896A
NZ516896A NZ516896A NZ51689600A NZ516896A NZ 516896 A NZ516896 A NZ 516896A NZ 516896 A NZ516896 A NZ 516896A NZ 51689600 A NZ51689600 A NZ 51689600A NZ 516896 A NZ516896 A NZ 516896A
Authority
NZ
New Zealand
Prior art keywords
groups
chosen
hydrogen
quino
phenanthrolin
Prior art date
Application number
NZ516896A
Inventor
Evelyne Delfourne
Francis Darro
Jean Bastide
Robert Iss
Armand Frydman
Original Assignee
L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9910490A external-priority patent/FR2797445B1/en
Priority claimed from FR0006652A external-priority patent/FR2809399B1/en
Application filed by L Lab filed Critical L Lab
Publication of NZ516896A publication Critical patent/NZ516896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention concerns a pharmaceutical composition comprising an efficient amount of a compound selected among the compounds of formulae (I) and (Ia) wherein: R1, R2, R3, R4, R5, R6 and R7 are as defined in Claim 1. Said compounds have interesting cytotoxic properties leading to a therapeutic use as antitumoral medicines.

Description

New Zealand Paient Spedficaiion for Paient Number 516896 516896 Ascididemin derivatives and their therapeutic applications The present invention relates to pharmaceutical compositions based on polyaromatic compounds that are 5 useful especially as antitumor drugs.
In 1999, the cytotoxic treatments (chemotherapy) used to reduce the size of cancer tumors, to curtail the development of the tumor process or even, in all to few 10 cases still, to eliminate the lumps of cancerous cells and the risk of metastases, combine recently introduced chemical substances with others that have been used for several decades. For example, 5-fluorouracil (5-FU), which has been known for nearly 40 years as one of the 15 most active treatments in colorectal cancer, can be replaced one or other of the specific topoisomerase I inhibitors (irinotecan or topotecan) when the tumor is no longer sensitive to 5-FU. More generally, the therapeutic arsenal available to treat colorectal 20 tumors will also be enriched by the availability of oxaliplatin, novel in situ "donors" of 5-FU or selective inhibitors of thymidylate synthase. This co-existence is not limited to the treatment of colorectal cancers, since the chemotherapy of cancer of 25 the breast, of the ovaries or of the lungs now also widely uses the family of taxane derivatives (paclitaxel and docetaxel). The need for treatments that are more effective and better tolerated, thus improving the survival and the quality of life of the 30 patients, is imperative since, taking once again the example of colorectal tumors, it has been estimated (S.L. Parker, T. Tong, S. Bolden et al., CA Cancer J. Clin., 1997) that in the United States alone, more than 131 000 new cases were diagnosed in 1997, 54 000 35 of which wre responsible for the death of the patients. It is the knowledge of this situation which has incited the inventors to become interested in a family of polyaromatic compounds that are still relatively poorly 'NTELLECTUAL PROPERTY OFFICE OF N.Z. 27 nov 2003 RECEIVED studied, identified in Ascidians of warm seawaters, to develop a novel medicinal chemistry intended to select synthetic compounds derived from a design/chemical modulation study and having significant therapeutic 5 cytotoxic activity.
The seas and oceans which cover more than 7 0% of the surface of the globe harbor marine plants and sponges whose gradual systematic pharmacognosic study shows 10 that these living species can contain complex alkaloids that have advantageous pharmacological properties. For example, the sponges Cryptotheca crypta and Halichondria okadai have been the subject of extensive studies since the discovery of the presence, in their 15 cells, of cytarabine or of halichondrine B. This is likewise the case for the family of tunicates, since the isolation of aplidin from the tunicate Aplidium albicans which lives in the Balearic islands (Spain). Alkaloids of tetrahydroisoquinolone structure have been 20 isolated from the ascidian Ecteinascidia turbinata. Among these, ecteinascidin-743 has been the subject of extensive preclinical studies (E. Igbicka et al. , NCI-EORTC symposium, 1998; Abst. 130 p. 34), and also clinical trials intended to define its therapeutic 25 potential as an anticancer drug (A. Bowman et al., NCI-EORTC symposium, 1998; Abst. 452 p. 118; M. Villanova-Calero et al., NCI-EORTC symposium, 1998; Abst. 453 p. 118; M.J.X. Hillebrand et al., NCI-EORTC symposium, 1998; Abst. 455 p. 119; E. Citkovic et al., 30 NCI-EORTC symposium, 1998; Abst. 456 p. 119). Novel pentacyclic acridine derivatives have also been the subject of pharmacochemical studies (D.J. Hagan et al., J. Chem. Soc., Perkin Transf., 1997; 1: 2739-2746).
Another natural alkaloid of marine origin, ascididemin, has been extracted from the tunicate Didemnum sp. (J. Kobayashi et al., Tetrahedron, lett. 1988; 29: 1177-80) and from the ascidian Cystodytes dellechiajei (I. Bonnard et al., Anti-cancer Drug design 1995; 10: 333-46). Ascididemin possesses antiproliferative properties demonstrated on the model of mouse leukemia (lines P388 or L1210) and described by F. Schmitz et al. (J. Org. Chem. 1991; 56: 804-8), B. Lindsay et al. 5 (Bioorg. Med. Chem. Lett. 1995; 5: 739-42) and J. Kobayashi et al. (Tetrahedron lett. 1988; 29: 1177-80) and on the model of human leukemia described by I. Bonnard et al. (Anti-cancer Drug design 1995; 10: 333-46). Several routes for synthesizing ascididemin 10 have been reported by various authors: F. Bracher et al. (Heterocycles 1989; 29: 2093-95), C.J. Moody et al. (Tetrahedron Lett. 1992; 48: 3589-602) and G. Gellerman et al. (Synthesis 1994; 239-41).
Mention may also be made of 2-bromoleptoclinidone (according to the naming by S.J. Bloor et al. 1987) isolated from the ascidian Leptoclinides sp. by S.J. Bloor et al. (J. Ann. Chem. Soc. 1987; 109: 6134-6) and synthesized by F. Bracher et al. 20 (Heterocycles 1989; 29: 2093-95) and then by M.E. Jung et al. (Heterocycles 1994; 39; 2: 767-778) . 2-Bromoleptoclinidone shows cytotoxicity on the cellular model of leukemia with an ED5o of 0.4 The cytotoxic properties were confirmed by F. Bracher 25 (Pharmazie 1997; 52: 57-60) both in vitro - on sixty tumor cell lines in culture - and in vivo on models of xenographs of human tumor cell lines (colon tumors SW-620 and HTC116, renal tumor A498 and melanoma LOX IM VI) implanted into mice.
Other compounds derived from ascididemin, such as 11-hydroxy ascididemin, 11-methoxy ascididemin, 11-phenyl and 11-nitrophenyl ascididemin, 1-nitro and 3-nitro ascididemin and neocalliactin have been 35 chemically described (according to the numbering by S.J. Bloor et al. 1987) by various teams such as those of F.J. Schmitz (J. Org. Chem. 1991; 56: 804-8) and Y. Kitahara et al. (Heterocycles 1993; 36: 943-46; Tetrahedron Lett. 1997; 53, 17029-38), G. Gellerman et intellectual property OFFICE OF N.Z. 27 nov 2003 - 4 " RECEIVED al. (Tetrahedron lett. 1993; 34: 1827-30), S. Nakahara et al (Heterocycles 1993; 36: 1139-44), I. Spector et al. (US Patent Number: 5,432,172, Jul. 11, 1995).
One subject of the present invention is a pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of general formulae I and la below for treating, by virtue of their cytotoxic properties, cancerous tumors and their metastases: in which: - X is chosen from oxygen, an =NH group and an 15 =N-OH group, Ri is chosen from hydrogen, halogens, a nitro group and groups -NR8R9 in which Rs and R9 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, - R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (C1-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from hydrogen, (C1-C4) 25 alkyl groups, (C1-C4) phenylalkyl groups and groups -.(CH2) n~Y with Y being chosen from halogens and CN, -CH (O-Et) 2f (Ci-C6) alkoxy, -O-(CH2) 2~N (CH3) 2 and -N(CH3)2 groups and n = 1 to 3, R4 is chosen from hydrogen, halogens, nitro 30 groups and groups -NR12R13 in which R12 and Ri3 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, - 5 intellectual property office of n.z. 2 7 nov 2003 RECEIVED R5, R6 and R7 are chosen from: hydrogen or a halogen atom, Ci-C6 alkyl, hydroxyl, C1-C6 alkoxy, (Ci-Ce) -alkoxy (Ci-Ce) alkyl, (C1-C4) alkylcarbonyloxy (C1-C4) alkyl, 5 -CHO, -COOH, -CN, -CO2R14, -CONHR14 and -CONR14R15 groups, -NHCOR14 and -NR14R15 in which R14 and R15 are chosen, independently of each other, from hydrogen and (Ci-Ce) alkyl, -phenyl-CO-CH3 and -CH2-CH2-N (CH3) 2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3) 2, morpholino, nitro or S03H groups, groups: -CH2-N-COOR16 , -Chfe-N-COOR16, ■ CH2-COOR17 CH2-Ar Ri6 and Ri7 being chosen from Ci-C6 alkyl groups and Ar being a C6-Ci4 aryl group, with the exclusion of the compounds of formula I containing the combination: x = o, and, either : Ri, R2, R3, R4, R5/ ^6, R7 = H, or : Ri, R3, R4, Rs, R6, R7 = H and R2 = Br, or R1( R2, R3, R4» Re, R? = H and Rs = OH and with the exclusion of the compound formula la containing the combination X = O and Ri, R2, R3, R4, R5, r6/ r7 = H, and the addition salts of these compounds with pharmaceutically acceptable acids.
, The present invention relates more particularly to a pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of formula I in which: - X is chosen from oxygen, an =NH group and an =N-OH group, - Rx is chosen from hydrogen, halogens, a nitro group and groups -NRsRg in which R8 and Rg are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, intellectual property office of n.Z. 2 7 nov 2003 RECEIVED independently of each other, from hydrogen and (C1-C4) alkyl groups, R.2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) 5 alkyl groups, (Ci-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl, - (CH2) 2-N (CH3) 2, and - (CH2)2-0-(CH2)2-N(CH3)2 groups, - R4 is chosen from hydrogen, halogens, nitro groups and groups -NR12R13 in which Ri2 and R13 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: 15 hydrogen or a halogen atom, C\-Ce alkyl, hydroxyl, C1-C6 alkoxy, -CHO, -COOH, -CN, -C02Ri4, -CONHR14 and -CONR14R15 groups, NHCOR14 and -NR14R15 groups in which Ri4 and R15 are chosen, independently of each other, from hydrogen and 20 (Ci-C6) alkyl and -CH2-CH2-N (CH3) 2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3) 2, morpholino, nitro or S03H groups, groups: -CH2 -N-COOR16 , -CH2- N-COOR16, CH2-COOR17 CH2-Ar Ri6 and R17 being chosen from C1-C6 alkyl groups and Ar being a C6-C14 aryl group, with the exclusion of the compounds in which X = 0, 30 and, either : Ri, R2, R3, Ro Rs? R6> R7 = H, or : Ri, R3, R4, R5, Rer R7 = H and R2 = Br, or Ri, R2/ R3, R4, R6, R7 = H' and R5 = OHf and the addition salts of these compounds with pharmaceutically acceptable acids.
One subject of the present invention is more particularly a pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of formula I in which: X represents oxygen, Ri is chosen from hydrogen and an amino group, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Ri0 and R11 are chosen, 10 independently of each other, from hydrogen, methyl groups, (C1-C4) phenylalkyl, - (CH2) 2-N (CH3) 2, (CH2)2-0-(CH2) 2-N (CH3) 2 groups, R4 is chosen from hydrogen, halogens and nitro and amino groups, - R5, R6 and R7 represent a hydrogen, with the exclusion of the compounds in which Ri, R2/ R-3/ R4 r R51 R6/ R7 = H, or Ri, R3, R4, R5/ R-6, R7 = H and R2 = Br, and the addition salts of these compounds with 20 pharmaceutically acceptable acids.
In its preferred form, one subject of the present invention is more particularly a pharmaceutical composition comprising an effective amount of a 25 compound chosen from the compounds of formulae I and la in which: X represents oxygen, Ri is chosen from hydrogen and an amino group, - R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from hydrogen, methyl 35 groups, (C1-C4) phenylalkyl groups and groups -(CH2)n-Y with Y being chosen from halogens and groups CN, -CH(0-Et) 2, (Ci-C6) alkoxy, -O- (CH2) 2-N (CH3) 2 and -N(CH3)2 and n = 1 to 3, 8 (followed by page 8a) - — R.4 is chosen from hydrogen, halogens, and nitro and.amino groups, R5 is chosen from a hydrogen, a halogen and a methoxy group, R6 and R7 are chosen from hydrogen and C1-C6 alkoxy, (Ci-Ce) alkoxy (Ci-Ce) alkyl and -CH2OCOCH3 groups, with the exclusion of the compounds of formula I in which Ri, R2, R3, R4, R5, 1*6, R7 = H or Ri, R3, R4, R5, R6, R7 = H and R2 = Br, and of the compound of formula 10 la in which Ri, R2, R3r R4, Rs, R6, R7 = H, and the addition salts of these compounds with pharmaceutically acceptable acids.
A subject of the present invention is also the use of a 15 compound as defined above, for the manufacture of an anticancer drug.
A subject of the present invention is also the compounds of general formulae I and la & n X V Formula I Formula la in which: X is chosen from oxygen, an =NH group and an =N-OH group, ,-• Ri is chosen from hydrogen, halogens, a nitro group and groups -NR8R9 in which Re and R9 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (Ci-C*) alkyl groups, (Ci-C6) alkoxy groups, a 8a- I ^ f NOV 2003 (followed by page 8b) | RECElyen guanidino group, groups -NR10Rii in which-Ritr and Rxi are chosen, .independently of each other, from hydrogen, (Ci~C4) alkyl groups, (Ci~C4) phenylalkyl groups and groups -(CH2)n-Y with Y being chosen from halogens and CN, -CH(0-Et)2, (Ci~C6) alkoxy, -0- (CH2) 2_N(CH3) 2 and -N(CH3)2 groups and n = 1 to 3, R4 is chosen from hydrogen, halogens, nitro groups and groups -NRi2Ri3 in which Ri2 and Ri3 are chosen, independently of each other, from hydrogen and (Ci~C4) alkyl groups, Rs, R6 and R7 are chosen from: hydrogen or a halogen atom, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, (Ci-C6) alkoxy (Ci~C6) alkyl, (Ci~C4) alkylcarbonyloxy-(Ci-C4) alkyl, -CHO, -C00H, -CN, -C02Ri4, -C0NHRi4 and -CONRi4Ri5 groups, -NHC0Ri4 and -NRi4R15 in which Ri4 and R15 are chosen, independently of each other, from hydrogen and (C1-C6) alkyl, -phenyl-CO-CH3 and -CHa^CHa-N (CH3) 2 groups, . -phenyl-CO~CH3 or -phenyl-CO-CH=CH-N (CH3) 2, morpholino, nitro or S03H groups, groups: -CH2 - N—COOR19 , -CH2- 'N-COOR16, I I CI-fe-COORu Chb-Ar Ri6 and R17 being chosen from Ci~C6 alkyl groups and Ar being a Ce-Ci4 aryl group, with the exclusion of the compounds of formula I in which X = 0, and, ; either ri> r2, r3, ro Rs, R6/ R7 = H, or Ri, R3, R4, R5, R6/ R7 = H and R2 = Br, or Ri, R2, R4, Rs, R6, R7 — H and R3 = 0CH3, or Ri, R2, r3, R4, R6r R7 = H and R5 = OH or 0CH3, or Ri = N02 and R2, R3, R4, R5, R6, R7 =H, and with the exclusion of the compound formula la in which X = O and Rl7 R2, R3, R4, R5, R6, R7 = H, - 8b - (followed by page 9) and the addition salts of these compounds with pharmaceutically acceptable acids.
The expression ^addition salts with pharmaceutically acceptable acids" denotes salts which give the biological properties of the free bases, without having any adverse effects. These salts may be especially those formed with mineral acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid; acidic metal salts, such as disodium intellectual property OFFICE OF N.Z. 2 7 nov 2003 9 RECEIVED orthophosphate and monopotassium sulfate, and organic A subject of the present invention is also use of a 5 compound as defined above in the manufacture of an anticancer drug.
In general, the compounds of formula I are obtained according to the general reaction scheme described by lo F- Bracher et al. (Heterocycles 1989; 29: 2093-95) for ascididemin. According to this scheme, the compounds are prepared by oxidative amination of a 5,8-quinone substituted with a substituted ortho-aminoacetophenone, followed by cyclization of the diarylamine obtained 15 (compounds of the formula II) into an intermediate tetracyclic quinone (compounds of formula III). The enamine formed by reaction of the compound of formula III with dimethylformamide diethyl acetal gives the final derivative by cyclization: acids.
Scheme I Formula II HQOC2H5),N(CH3)2 DMF, 120°C ° CH> k, Formula: III (followed by page 10a) Ascididemin (or 9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one) was prepared according to the process described by F. Bracher et al. (Heterocycles 1989; 29: 2093-95) and is referenced, in the present document, under the 5 number CRL 8274.
A subject of the present invention is also a process for preparing a compound of formula la, in which: X is chosen from oxygen, an =NH group and an =N-OH group, Ri is chosen from hydrogen, halogens, a nitro group and groups -NReRg in which R8 and Rg are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-Cg) alkoxy groups, a guanidino group, groups -NRioRu in which Ri0 and Ru are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n~Y with Y being chosen from halogens and CN, -CH(0-Et)2, (Ci-C6) alkoxy, -0- (CH2) 2-N (CH3) 2 and —N (CH3) 2 groups and n = 1 from hydrogen, halogens, -NR12R13 in which R12 and R13 ^ r R4 is chosen nitro groups and groups - 10a -(followed by page 10b) are chosen, independently of each other, from hydrogen and (Ci-C4) alkyl groups, Rs, R6 and R7 are chosen from: hydrogen or a halogen atom, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, (Ci-C6) alkoxy (Ci-C6) alkyl, (C1-C4) alkylcarbonyloxy-(C1-C4) alkyl, -CHO, -COOH, -CN, -C02Ri4, -CONHR14 and -CONR14R15 groups, -NHCOR14 and -NRi4Ri5 in which Ri4 and R15 are chosen, independently of each other, from hydrogen and (C1-C6) alkyl, -phenyl-CO-CH3 and -CH2-CH2-N (CH3) 2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3)2, morpholino, nitro or S03H groups, groups: -CH2 — N -COOR16 I CH2-COOR17 -CH2-N-COOR16, C^-Ar Ri6 and Ri7 being chosen from C3.-C6 alkyl groups and Ar being a C6-Ci4 aryl group, which consists in: a - condensing a chlorobenzoic acid of formula; ho2c with a dimethoxyaniline of formula: 2 7 NOV 2003 Received - 10b - (followed by page 10c) OMe OMe to give a compound of formula Ila. b cyclizing the compound of formula Ila to give a compound of formula: OMe c — converting the compound into a quinone of formula Ilia: PROPERTY ©fflce of n.z. 27 nov 2003 RECEIVED - 10c - (followed by page lOd) d - reacting the quinone of formula Ilia with an azadiene of formula: to give a compound of formula IVa: ch3 r» e - reacting the compound of the formula- IVa with dimethylformamide diethyl acetal to give the compound of formula la, f - and, optionally, converting the compound thus obtained into another compound of formula la. intellectual property OFFICE OF N.Z. 2 7 nov 2003 RECEIVED - lOd - (followed by page lOe) A subject of the present invention is also a process for preparing compounds of general formula I, of formula: in which: Ri is chosen from hydrogen, halogens, a nitro group and groups -NRsRg in which Re and R9 are. chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n--Y with Y being chosen from halogens and CN, -CH(0-Et)2, (Ci-Cg) alkoxy, -0-(CH2) 2-N (CH3) 2 groups and -N(CH3)2 and n = 1 to 3, .R4 is chosen from hydrogen, halogens, nitro groups and groups -NR12R13 in which R12 and Rj3 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, Rg and R7 are chosen from: hydrogen or a halogen atom, v_>r iv.z. 21 NOV 2003 RECEl V £0 - lOe - (followed by page lOf) C1-C6 alkyl, hydroxyl,. C1-C6 alkoxy, (Ci-C6) alkoxy (Ci-Ce) alkyl, (C1-C4) alkylcarbonyloxy-(C1-C4) alkyl, -CHO, -COOH, -CN, -C02Ri4, -CONHR14 and -CONRi4Ri5 groups, -NHCOR14 and -NR14R15 in which R14 and R15 are chosen, independently of each other, from hydrogen and (C1-C6). alkyl, -phenyl-CO-CH3 and -CH2-CH2-N(CH3) 2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3)2, morpholino, nitro or S03H groups, groups: -CH2 -N-COOR-ie I CH2~COOR17 CH2-N_C00R16, CH2-Ar • Ri6 and R17 being chosen from C1-C6 alkyl groups and Ar being a C6-Ci4 aryl group, with the. exclusion of the compounds of formula I in which either Ri, R?, R3, R4, R5, R&, R7 = H, or Ri; R3j R4r Rs/ R7 = H and R2 = Br, or Ri, R2, R4, 1*5/ R6/ R7 = H and R3 — OCH3, or Ri, R2, R3, R4, R6^ R7 = H and R5 = OH or 0CH3 or Ri = N02 and R2, R3, R4, R5, R6, R7 = H, which consists .25 a) in reacting a hydroquinone of formula R5 0 with a compound of formula intellectual property OFFICE OF N.Z. 2 7 nov 2003 RECEIVED - lOf - (followed by page lOg) R1 h2n o.
Rs cha r* R, in the presence of CeCl3, 7H2O and ethanol to give a compound of formula II b) in converting the compound of' formula II into a compound of formula III FU O O CH3 R4 c) in reacting the compound of the formula III with HC (OC2H5) 2N (CH3) 2 in DMF at 120 °C to form a compound of formula IV ■R« O 2 7 NOV 2003 / ft ECE/ypp I - lOg - (followed by page lOh) d) in cyclizing the compound of formula IV to a compound of formula I in the presence of NH4CI and AcOH, e) optionally converting the compound of formula I- thus obtained into another compound of formula II.
A subject of the present invention is also a compound of formula N(CH3)2 in which:: Ri is chosen from hydrogen, halogens, a nitro group and groups -NR8Rg in which R8 and Rg are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-Ce) alkoxy groups, a guanidino group, groups -NR10R11 in which Ri0 and Rn are chosen, independently of each other, from hydrogen, (Ci-C4) alkyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n-Y with Y being chosen from halogens- and CN,.-CH(O-Et)2, (Ci-C6) alkoxy, -0- (CH2) 2-N (CH3) 2 and -N(CH3)2 groups and n = 1 to 3, R4 is chosen from hydrogen, halogens,, nitro . groups and groups -NR12R13 in which R12 and R13 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: INTELLECTUAL PROPERTY OFFICE OF N.Z. 2 7 nov 2003 RECEIVED - lOh - (followed by page lOi) hydrogen or a halogen atom, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, (Ci-C6) alkoxy (Ci~C6) alkyl, (C1-C4) alkylcarbonyloxy-(C1-C4) alkyl, -CHO, -COOH, -CN, -C02Ri4, -CONHR14 and -CONR14R15 groups, -NHCOR14 and -NRi4R15 in which R14 and R15 are chosen, independently of each other, from hydrogen and (Cj-Ce) alkyl, -phenyl-CO-CH3 and -CH2-CH2-N(CH3)2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3)2, morpholino, nitro or S03H groups, groups: -Chfe-N-COOR15 , >CH2-N-COOR16, CH2-COOR-I7 —Ar Ri6 and R17 being chosen from C1-C6 alkyl groups and Ar being a C6-Ci4 aryl group, with the exclusion of compounds in which either Ri, R2, • R3, R41 Rs-/ 1*6/ R7 p••■H, or Ri, R3, R4, R5/ 1*6/ R7 = H and R2 = Br, or Ri, R2, R4, R5, R6, R7 = H and R3 = OCH3, or Ri, R2, R3, R«/ 1*6/ R7 = H and R5 = OH or 0CH3 or Ri = N02- and R2, R3/ Ro Rs/ R6/ R7 = H, and the addition salts of these compounds with pharmaceutically acceptable acids.
INTELLECTUAL PROPERTY OFFICE OF N.Z. 2 7 nov 2003 RECEIVED - lOi - (followed by page 11) Certain compounds may be prepared directly from ascididemin or from a compound of formula I used as a synthetic intermediate.
Thus, in particular, the compounds of formula I in which R3 is a group -NRi0Rn, where Ri0 and/or Ru are other than hydrogen, may be obtained from a compound of formula I in which R3 is an -NH2 group.
Similarly, the compounds of formula la may be obtained according to the general reaction scheme II. According to this scheme, the compounds are prepared by coupling a substituted chlorobenzoic acid and dimethoxyaniline to form the compounds of formula Ila. After conversion of the acid function to a methyl ketone, cyclization and then oxidation, an intermediate tricyclic quinone (compound of formula Ilia) is obtained. A Diels-Alder cycloaddition with a 1-azediene leads to the formation of a tetracyclic quinone (compound of formula IVa). The addition of dimethylformamide diethyl acetal to this quinone gives an enamine intermediate which is cyclized, in the presence of ammonium chloride, to the final compound of formula la.
Scheme II OMe f A nh2 f + V ho2c OMe CI Fm OMe R, Cuo+ H H02C OMe R4 Formula Ila OMe |_j R., LiCH, OMe H+ CH3OC T ^R3 OMe R4 DMFDEA, NH.CI *5 N^.
Formula la AMENDED SHEET Certain compounds may be prepared directly from the ascididemin isomer known as 9-H-quino[4,3, 2-de]-[1,7]phenanthrolin-9-one, or from a compound of formula la used as a synthetic intermediate.
Thus, in particular, the compounds of formula la in which R3 is a group -NRi0Rn, in which Ri0 and/or Rn are other than hydrogen, may be obtained from a compound, of formula la in which R3 is a -NH2 group.
A — Preparation of the intermediate products of formula II (Scheme I) A-l - Synthesis of 6-(2-acetyl-4-methylphenylamino)-quinoline-5,8-dione (Intermediate Ax) (CRL 8322) A solution of 5,8-quinolinedione (0.215 g, 1.35 mmol) in 12 ml of ethanol is added slowly to a solution of cerium chloride (1 g, 2.7 mmol) and 5-methyl-2-amino-25 acetophenone (0.402 g, 2.7 mmol) in 5 ml of ethanol. The reaction medium (red) is stirred overnight at room temperature. The resulting medium is hydrolyzed with 30 ml of aqueous 10% acetic acid solution and extracted 4 times with chloroform. The organic phases are dried 30 over MgS04 and then evaporated. The crude product obtained is purified by flash chromatography on a column of silica (95/5 CH2Cl2/MeOH) to give 0.405 g of the expected tricyclic compound in the form of a powder: • Yield = 98% • 1H NMR (CDC13) : 2.42 (s, 3H) , 2.77 (s, 3H) , 6.86 (s, 1H) , 7.38 (dd, 1H, J = 8 and 1.6 Hz), 7.52 (d, 1H, J = 8 Hz), 7.61 (dd, 1H, J = 5.2 and 7.6 Hz), 7.74 (d, 1H, J = 1.6 Hz), 8.46 (dd, 1H, J = 7.6 and 5.2 Hz), 9.02 (dd, 1H, J = 2 and 5.2 Hz), 11.18 (s, 1H) .
A-2 - Synthesis of 6-(2-acetyl-4-5 chlorophenylamino)quinoline-5,8-dione (Intermediate A2) Preparation according to the process described in chapter A-l: quinoline-5,8-dione (0.188 g, 1.18 mmol), cerium chloride (0.88 g, 2.36 mmol), 5-chloro-2-10 aminoacetophenone (0.4 g, 3.14 mmol), ethanol (10 + 4 ml), acetic acid (25 ml). 0.3 g of a red powder is obtained: • Yield = 78% • 1H NMR (CDC13) : 2.65 (s, 3H) , 6.84 (s, 1H) , 7.52 15 (dd, 1H, J = 8.8 Hz), 7.57 (d, 1H, J = 8.8 Hz), 7.63 (dd, 1H, J = 8 and 4.4 Hz), 7.89 (d, 1H, J = 2.4 Hz), 8.46 (dd, 1H, J = 0.8 and 8 Hz), 9.02 (dd, 1H, J - 2 and 5.2 Hz), 11.18 (s, 1H). • 13C NMR (CDCI3) : 28.5; 107.36; 121.86; 126.69; 20 126.85; 127.49; 128.39; 132.10; 134.06; 134.75; 138.36; 143.29; 148.32; 155.22; 181.28; 182.63; 200.39.
A-3 - Synthesis of 6-(2-acetyl-4- benzylaminophenylamino)quinoline-5,8-dione 2 5 (Intermediate A3) Preparation according to the process described in chapter A-l: quinoline-5,8-dione (0.250 g, 1.57 mmol), cerium chloride (0.77 g, 3.14 mmol), 5-benzylamino-2-aminoacetophenone (0.603 g, 3.14 mmol), ethanol 30 (15 + 7 ml), acetic acid (35 ml). 0.56 g of a red powder is obtained: • Yield = 91% • XH NMR (CDCI3) : 2.54 (s, 3H) , 4.38 (s, 2H) , 6.70 (s, 1H) , 6.83 (dd, 1H, J = 9.6 and 3.2 Hz), 7.08 (d, 1H, J = 3.2 Hz), 7.30-7.37 (m, 5H) , 7.43 (d, 1H, J = 9.6 Hz), 7.58 (dd, 1H, J = 7.6 and 4.8 Hz), 8.43 (dd, 1H, J = 7.6 and 2 Hz), 9.03 (dd, 1H, J = 2 and 4.8 Hz), 10.67 (s, 1H) .
A-4 - Synthesis of 6-(2-acetyl-5- bromophenylamino)quinoline-5,8-dione (Intermediate A4) (CRL 8268) Preparation according to the process described by 5 F. Bracher, Liebigs Ann. Chem. 1990, 205-206.
A-5 - Synthesis of 6-(2-acetyl-4- dimethylaminophenylamino) quinoline-5,8-dione (Intermediate A5) Preparation according to the process described in chapter A-l: quinoline-5,8-dione (0.36 g, 2.26 mmol), cerium chloride (1.67 g, 4.49 mmol), 5-dimethylamino-2-aminoacetophenone (0.8 g, 4.49 mmol), ethanol (20 + 10 ml), acetic acid (50 ml). 1.26 g of a red 15 powder are obtained: • Yield = 84% • 1H NMR (CDC13) : 2.85 (s, 3H) , 3.12 (s, 6H) , 6.72 (s, 1H) , 6.90 (dd, 1H, J = 2.8 and 9.2 Hz), 7.15 (d, 1H, J = 2.8 Hz), 7.49 (d, 1H, J = 9.2 Hz), 7.58 (dd, 1H, J = 8 Hz and 4.4 Hz), 8.43 (dd, 1H, J = 1.6 and 8 Hz), 9.00 (dd, 1H, J = 1.6 and 4.4 Hz), 10.69 (s, 1H) .
A-6 - Synthesis of 6-(2-acetyl-4-25 methoxyphenylamino)quinoline-5,8-dione (Intermediate A6) Preparation according to the process described in chapter A-l: quinoline-5,8-dione (3.51 g, 22.08 mmol), cerium chloride (16.4 g, 44.03 mmol), 5-methoxy-2-30 aminoacetophenone (7.29 g, 44.18 mmol), ethanol (200 + 90 ml), acetic acid (500 ml). 4.25 g of a red powder are obtained: • Yield = 60% • XH NMR (CDCI3) : 2.65 (s, 3H) , 3.87 (s, 3H) , 6.76 35 (s, 1H) , 7.12 (dd, 1H, J = 2.8 and 8.8 Hz), 7.42 (d, 1H, J = 2.8 Hz), 7.55 (d, 1H, J = 8.8 Hz), 7.61 (dd, 1H, J = 7.6 and 4.4 Hz), 8.45 (dd, 1H, J = 1.6 and 7.6 Hz), 9.01 (dd, 1H, J = 1.6 and 4.4 Hz), 10.80 (s, 1H) .
A-7 - Synthesis of 4,6-bis(2-acetylanilino)quinoline-5,8-dione (Intermediate A7) Preparation according to the process described in 5 chapter A-l: 4-chloroquinoline-5,8-dione (3.5 g, 18 mmol), cerium chloride (13.5 g, 36.24 mmol),2-aminoacetophenone (4.4 ml, 36 mmol), ethanol (160 + 70 ml), acetic acid (400 ml) . 2.32 g of a red powder are obtained: • Yield = 30% • XH NMR (CDC13) : 2.69 (s, 3H) , 2.72 (s, 3H), 6.85 (s, 1H) , 7.18 (ddd, 1H, J = 7.6 and 7.6 and 0.8 Hz), 7.28 (m, 1H) , 7.30 (d, 1H, J = 6.4 Hz), 7.54-7.59 (m, 3H) , 7.63 (d, 1H, J = 7.6 Hz), 7.91 (dd, 1H, J = 1.6 and 8.4 Hz), 7.94 (dd, 1H, J = 1.2 and 8.4 Hz), 8.47 (d, 1H, J = 6.4 Hz), 11.35 (s, 1H), 12.35 (s, 1H).
A-8 - Synthesis of 6-(2-acetyl-4-bromophenylamino)-4-methoxyquinoline-5,8-dione (Intermediate As) Preparation according to the process described in chapter A-l: 4-methoxyquinoline-5,8-dione (1.57 g, 9.1 mmol), cerium chloride (3.1 g, 8.3 mmol), 5-bromo-2-aminoacetophenone (Leonard, Boyd, J. Org. Chem. 1946; 11, 419-423) (1.95 g, 9.1 mmol), ethanol (200 ml), 25 acetic acid (180 ml). After purification by flash chromatography on a column of silica (95/5 CH2Cl2/MeOH), 1.22 g of an orange powder are obtained: • Yield = 37% • XH NMR (CDCI3) : 3.15 (s, 3H) , 4.58 (s, 3H) , 7.61 30 (d, 1H, J = 6 Hz), 7.74 (s, 1H) , 7.99 (d, 1H, J = 8.8 Hz), 8.14 (dd, 1H, J = 8.8 and 2.4 Hz), 8.51 (d, 1H, J = 2.8 Hz), 9.32 (d, 1H, J = 6 Hz), 11.68 (s, 1H).
A-9 - Synthesis of 2-methoxy-6-(2-35 acetylphenylamino)quinoline-5,8-dione (Intermediate A9) A solution of o-aminoacetophenone (0.41 g, 3.1 mmol) in ethanol (6 ml) is added to a suspension of 2-methoxy-quinoline-5,8-dione (0.54 g, 2.8 mmol) and cerium chloride (1.16 g, 4.7 mmol) in ethanol (100 ml). The reaction medium is stirred at room temperature for 40 hours. After concentration on a rotary evaporator, the crude product obtained is purified by filtration on 5 silica (98/2 CHCl3/heptane) to give the expected codensation product in the form of a red powder (0.35 g).
• Yield = 38% • Melting point = 258°C • 1H NMR (CDC13) : 2.67 (s, 3H) , 4.15 (s, 3H) , 6.79 (s, 1H) , 6.98 (d, 1H, J = 8.8 Hz), 7.18 (ddd, 1H, J = 8.1, 8.4 and 1.5 Hz), 7.56 (dd, 1H, J = 8.4 and 1.5 Hz), 7.61 (ddd, 1H, J = 8.1 and 8.4 and 1.1 Hz), 7.94 (dd, 1H, J = 8.1 and 1.5 Hz), 8.31 (d, 1H, J = 15 8 . 8 Hz) . • 13C NMR (CDCI3) : 28.51, 54.73, 106.02, 115.22, 120.78, 122.50, 123.11, 125.70, 132.34, 134.24, 137.18, 140.05, 143.30, 148.21, 167.75, 180.88, 183.05, 201.41.
• IR (CHCI3) : 1668, 1644 cm"1 A-10 - Synthesis of 3-hydroxymethyl-6-(2- acetylphenylamino)quinoline-5,8-dione (Intermediate Ai0) a) - 3-Hydroxymethyl-5,8-dimethoxyquinoline A solution of 1M LiAlH4/Et20 (5 ml, 5 mmol) is added dropwise and under nitrogen to a solution of ethyl 5,8-dimethoxyquinoline-3-carboxylate (180 mg, 0.689 mmol) in 60 ml of THF. The mixture is stirred at room 30 temperature for 15 hours and then poured into 15 ml of IN NaOH and 40 ml of water. After extraction with CH2CI2 (3 x 100 ml) and then drying of the organic phase over MgS04, the extract is concentrated on a rotary evaporator. The crude product obtained is purified by 35 flash chromatography (95/5 CH2Cl2/MeOH) to give the expected product in the form of a brown powder (72 mg): • Yield = 48% • Melting point = 150°C • NMR (CDCI3) : 3.92 (s, 3H) , 4.00 (s, 3H) , 4.88 (s, 2H) , 6.72 (d, 1H, J = 8.4 Hz), 6.88 (d, 1H, J = 8.4 Hz), 8.47 (d, 1H, J = 2.2 Hz), 8.87 (d, 1H, J = 2.2 Hz) • 13C NMR (CDCI3) : 55.76, 56.00, 63.09, 103.95, 106.70, 121.25, 128.62, 133.35, 139.80, 148.61, 149.21, 149.41.
• IR (CDCI3) : 3607, 3417, 1622, 1605 cm"1. b) - 3-Hydroxymethyl-5,8-dimethoxyquinoline A solution of 3-hydroxymethyl-5,8-dimethoxyquinoline (55 mg, 0.25 mmol) and cerium ammonium nitrate (550 mg, 1 mmol) in a CH3CN/H20 mixture (3 ml/1 ml) is stirred at room temperature for 40 minutes. After addition of 5 ml 15 of H20 and 10 ml of saturated NaHCC>3 solution, the medium is extracted with CH2CI2 (6 x 30 ml) and the organic phases are dried over MgSC>3. After evaporating off the solvent on a rotary evaporator, the expected quinone is obtained in the form of a brown powder 20 (11 mg) : • Yield = 22% • Melting point = 150°C • XH NMR (CDCI3) : 4.95 (s, 2H) , 7.06 (d, 1H, J = 10.2 Hz), 7.15 (d, 1H, J = 10.2 Hz), 8.43 (s, 1H) , 9.03 (s, 1H) . • 13C NMR (CDCI3) : 62.03, 128.86, 132.26, 138.00, 139.11, 141.33, 146.58, 153.10, 183.12, 184.54.
• IR (CHCI3) : 3413, 1680, 1596 cm"1. c) - Synthesis of 3-hydroxymethyl-6-(2-acetylphenyl-amino) quinoline-5 , 8-dione (Intermediate Ai0) A solution of 2-aminoacetophenone (0.18 g, 1.33 mmol) is added to a suspension of 3-hydroxymethylquinoline-5,8-dione (0.22 g, 1.16 mmol) and cerium chloride 35 (0.6 g, 2.43 mmol) in ethanol (40 ml). The reaction medium is stirred at room temperature in darkness for 3 hours. After concentrating on a rotary evaporator, the crude product obtained is purified by filtration on silica (98/2 CH2Cl2/MeOH) to give the expected V condensation product in the form of a violet powder (0.16 g): • Yield = 42% • Melting point = 258°C • XH NMR (DMSO-de) : 2.67 (s, 3H) , 4.73 (d, 2H, J = .5 Hz), 5.67 (t, 1H, J = 5.5 Hz), 6.64 (s, 1H) , 7.30 (m, 1H) , 7.71 (m, 2H) , 8.12 (d, 1H, J = 8.0 Hz), 8.35 (d, 1H, J = 2.0 Hz), 8.93 (d, 1H, J = 2.0 Hz), 11.02 (s, 1H) . • 13C NMR (CDC13) : 28.81, 60.08, 106.52, 120.96, 123.44, 126.14, 127.23, 131.52, 132.69, 134.43, 138.91 141.75, 143.55, 146.62, 152.81, 181.62, 181.84, 202.02.
• IR (CHCI3) : 3440, 1690, 1661, 1640 cm"1.
B - Preparation of the intermediate products of formula III (Scheme II) B-l - Synthesis of 9,11-dimethyl-l,6-diazanaphthacene-20 5,12-dione (Intermediate Bi) (CRL 8324) 1.9 ml of sulfuric acid dissolved in 9.6 ml of acetic acid are added slowly to a solution of tricyclic intermediate Ai (0.4 g, 1.3 mmol) in 12 ml of acetic acid. The reaction medium is refluxed for 30 minutes 25 and, after cooling, is then poured into a beaker containing crushed ice. The mixture is neutralized with NH40H and then extracted 4 times with dichloromethane. The organic phases are dried over MgSCU and then evaporated. The crude product obtained is purified by 30 flash chromatography on a column of silica (95/5 CH2Cl2/MeOH) to give 0.325 g of the expected tetracyclic compound.
• Yield = 86% • XH NMR (CDCI3) : 2.64 (s, 3H) , 3.29 (s, 3H) , 7.74 35 (dd, 1H, J = 7.6 and 4.8 Hz), 7.75 (dd, 1H, J = 8.4 and 1.6 Hz), 8.12 (dd, J = 1.6 Hz), 8.33 (d, 1H, J = 8.4), 8.71 (dd, 1H, J = 2 and 7.6 Hz), 9.13 (dd, 1H, J = 2 and 4.8 Hz).
B-2 - Synthesis of 9-chloro-ll-methyl-l,6- diazanaphthacene-5,12-dione (Intermediate B2) Preparation according to the process described in chapter B-l: tricyclic intermediate A2 (0.289 g, 5 0.88 mmol), sulfuric acid (1.3 ml), acetic acid (8 + 6.5 ml). After purification by flash chromatography (95/5 CH2Cl2/MeOH) , 0.26 g of tetracycle is obtained: • Yield = 95% • XH NMR (CDC13) : 3.25 (s, 3H) , 7.76 (dd, 1H, J = 8 and 4.8 Hz), 7.85 (dd, 1H, J = 8.8 and 2 Hz), 8.33 (dd, 1H, J = 2 Hz), 8.38 (d, 1H, J = 8.8), 8.71 (dd, 1H, J = 1.6 and 8 Hz), 9.15 (dd, 1H, J = 1.6 and 4.8 Hz).
B-3 - Synthesis of 9-benzylamino-ll-methyl-l,6- diazanaphthacene-5,12-dione (Intermediate B3) Preparation according to the process described in chapter B-l: tricyclic intermediate A3 (4 g, 10 mmol), sulfuric acid (15.1 ml), acetic acid (92 + 75 ml). 20 After work-up, 3.58 g of tetracycle are obtained.
• Yield = 98% • XH NMR (CDCI3) : 3.09 (s, 3H) , 4.52 (d, 2H) , 4.86 (t, 1H) , 7.06 (d, 1H, J = 2.8 Hz), 7.29 (dd, 1H, J = 9.2 and 2.8 Hz), 7.3-7.43 (m, 5H) , 7.71 (dd, 1H, J = 4.8 and 8 Hz), 8.20 (d, 1H, J = 9.8 Hz), 8.69 (dd, 1H, J = 1.6 and 8 Hz), 9.09 (dd, 1H, J = 1.6 and 4.8 Hz).
B-4 - Synthesis of 8-bromo-ll-methyl-l,6- diazanaphthacene-5,12-dione (Intermediate B4) Preparation according to the process described by F. Bracher, Liebigs Ann. Chem. 1990, 205-206.
B-5 - Synthesis of 9-dimethylamino-ll-methyl-l,6-diazanaphthacene-5,12-dione (Intermediate B5) Preparation according to the process described in chapter B-l: intermediate tricycle A5 (0.7 6 g, 2.27 mmol), sulfuric acid (3.5 ml), acetic acid (20 + 18 ml). After work-up, 0.67 g of tetracycle is obtained.
• Yield = 93% • XH NMR (CDCI3) : 3.17 (s, 3H) , 3.21 (s, 6H) , 7.04 (d, 1H, J = 3.2 Hz), 7.51 (dd, 1H, J = 3.2 and 9.2 Hz), 7.71 (dd, 1H, J = 8 and 4.4 Hz), 8.26 (d, 1H, J = 9.2 Hz), 8.7 (dd, 1H, J = 1.6 and 8 Hz) 9.09 (dd, 1H, J = 1.6 and 4.4 Hz).
B-6 - Synthesis of 9-methoxy-ll-methyl-l,6- diazanaphthacene-5,12-dione (Intermediate B6) Preparation according to the process described in chapter B-l: intermediate tricycle As (4.25 g, 13.18 mmol), sulfuric acid (20 ml), acetic acid (110 + 100 ml). The product obtained by flash chromatography (100/3 CH2Cl2/MeOH) is washed with ethyl 15 ether to give 2.9 g of tetracycle.
• Yield = 72% • 1R NMR (CDCI3) : 3.25 (s, 3H), 4.02 (s, 3H) , 7.49 (d, 1H, J = 3.3 Hz), 7.56 (dd, 1H, J = 3.3 and 9.3 Hz), 7.74 (dd, 1H, J = 8.3 and 4.3 Hz), 8.34 (d, 1H, J = 9.3 Hz), 8.71 (dd, 1H, J = 2.5 and 8.3 Hz), 9.12 (dd, 1H, J = 2.5 and 4.3 Hz).
B-7 - Synthesis of 4-(2-acetylanilino)-11-methyl-l,6-diazanaphthacene-5,12-dione (Intermediate B7) 25 (CRL 8332) Preparation according to the process described in chapter B-l: intermediate tricycle A7 (1 g, 2.35 mmol), sulfuric acid (3.5 ml), acetic acid (18 ml). The product obtained by flash chromatography (100/3 30 CH2Cl2/MeOH) is washed with ethyl ether to give 0.6 g of tetracycle in the form of an orange powder.
• Yield = 63% • 1H NMR (CDCI3) : 2.59 (s, 3H) , 3.25 (s, 3H), 7.29 (ddd, 1H, J = 7.2 and 7.2 and 1.2 Hz), 7.37 (d, 1H, J = 6 Hz), 7.54 (ddd, 1H, J = 6.8 and 6.8 and 1.6 Hz), 7.59 (d, 1H, J = 6.8 Hz), 7.74 (dd, 1H, J = 7.2 and 1.2 Hz), 7.76 (dd, 1H, J = 6.8 and 1.6 Hz), 7.87-7.918 (m, 2H), 8.34 (d, 1H, J = 8.4 Hz), 8.43 (d, 1H, J = 8.4 Hz), 8.54 (d, 1H, 6 Hz), 12.5 (s, 1H).
B-8 - Synthesis of 4-methoxy-9-bromo-ll-methyl-l,6-diazanaphthacene-5,12-dione (Intermediate Bs) Preparation according to the process described in chapter B-l: intermediate tricycle As (1.22 g, 5 3.04 mmol), sulfuric acid (4.5 ml), acetic acid (27 + 23 ml) . The product obtained by flash chromatography (100/3 CH2Cl2/MeOH) is washed with ethyl ether to give 0.76 g of tetracycle in the form of a yellow powder.
• Yield = 65% • XH NMR (CDC13) : 3.21 (s, 3H) , 4.10 (s, 3H) , 7.18 (d, 1H, J = 6 Hz), 7.96 (dd, 1H, J = 8.8 and 2 Hz), 8.27 (d, 1H, J = 8.8 Hz), 8.47 (d, 1H, J = 2 Hz), 8.89 (d, 1H, J = 6 Hz) .
B-9 - Synthesis of 2-methoxy-ll-methyl-l,6- diazanaphthacene-5,12-dione (Intermediate B9) A solution of 2-methoxy-6- (2- acetylphenylamino)quinoline-5,8-dione (0.34 g, 1.1 mmol) in an acetic acid/sulfuric acid mixture (25 mol/2.7 ml) is heated at 90°C for 45 minutes. After cooling, the reaction medium is poured into a water/ice mixture (200 ml) and then basified to pH 8 with K2C03 and extracted with CHCI3 (3 x 200 ml) . The organic 25 phases are dried over MgSO-j and then concentrated on a rotary evaporator. The crude product obtained is purified by filtration on silica (CHCI3) to give the expected tetracycle in the form of a beige-colored powder (0.23 g): • Yield = 71% • Melting point = 260°C • XH NMR (CDCI3) : 3.32 (s, 3H) , 4.23 (s, 3H) , 7.14 (d, 1H, J = 8.8 Hz), 7.79 (ddd, 1H, J = 8.6, 8.4 and 1.2 Hz), 7.91 (ddd, 1H, J = 8.4, 8.6 and 1.2 Hz), 8.38 (dd, 1H, J = 8.6 and 1.2 Hz), 8.46 (dd, 1H, J = 8.4 and 1.2 Hz), 8.58 (d, 1H, J = 8.8 Hz). • 13C NMR (CDCI3) : 16.63, 54.76, 117.29, 125.29, 125.50, 125.64, 129.62, 129.75, 132.37, 132.57, 138.12, 147.73, 148.63, 149.69, 152.28, 167.77, 181.10, 183.55.
• IR <CHC13) : 1683, 1599 cm"1 B-10 - Synthesis of 3-acetoxymethyl-ll-methyl-l,6-diazanaphthacene-5,12-dione (Intermediate Bi0) A solution of 3-hydroxymethyl-6-(2-acetylphenylamino)-quinoline-5,8-dione (Intermediate Aio) r (0.248 g, 0.77 mmol) in an acetic acid/sulfuric acid mixture (16 ml/1.3 ml) is heated at 90°C for 2 hours 30 minutes. After cooling, the reaction medium is 10 poured into a water/ice mixture (15 ml) and then basified to pH 9 with Na2C03. The medium is then extracted with CH2C12 (3 x 150 ml) . The organic phases are dried over MgSCU and then concentrated on a rotary evaporator. The crude product obtained is purified by 15 filtration through silica (98/2 CH2Cl2/MeOH) to give the expected compound in the form of a brown powder (0.21 g).
• Yield = 85% • Melting point = 210°C • XH NMR (CDC13) : 2.18 (s, 3H) , 3.30 (s, 3H) , 5.31 (s, 2H) , 7.78 (ddd, 1H, J = 1.1, 6.8 and 8.1 Hz), 7.92 (ddd, 1H, J = 1.1, 6.8 and 8.1 Hz), 8.37 (dd, 1H, J = 8.1 and 1.1 Hz), 8.43 (dd, 1H, J = 8.1 and 1.1 Hz), 8.66 (d, 1H, J = 2.2 Hz), 9.09 (d, 1H, J = 2.2 Hz). 25 • 13C NMR (CDCI3) : 16.06, 20.11, 62.06, 124.81, 124.91, 129.06, 129.18, 129.29, 131.70, 132.18, 134.06, 136.09, 146.86, 147.97, 149.01, 152.19, 154.30, 169.72, 180.96, 182.34.
IR (CHCI3) : 3420, 1746, 1692 cm"1 C - Preparation of the intermediate products of formula Ilia (Scheme II) 1) Synthesis of N-(2,5-dimethoxyphenyl)anthranilic acid (Compound 4) A mixture of 2-chlorobenzoic acid (9.2 g, 60 mmol), dimethoxyaniline (10 g, 65 mmol), copper (0.96 g), Cu20 (0.96 g) and K2CO3 (10.4 g) in 120 ml of diglyme is refluxed overnight. After evaporating off the solvent, the reaction medium is basified with IN .sodium hydroxide. Ether is added and the medium is then filtered through silica and the ether phase is removed.
The aqueous phase is acidified with concentrated HC1 and then extracted with ethyl acetate. After drying over MgSC>4 and evaporating off the solvent on a rotary evaporator, the crude product obtained is purified by filtration through silica (CH2CI2) to give the expected 10 condensation product in the form of a yellow powder (14.5 g).
• Yield = 89% • Melting point = 138°C • XH NMR (CDCI3) : 3.77 (s, 3H) , 3.85 (s, 3H) , 6.57 15 (dd, 1H, J = 8.8 and 2.9 Hz), 6.77 (ddd, 1H, J = 1.9 and 7.5 Hz), 6.87 (d, 1H, J = 9.2 Hz), 7.04 (d, 1H, J = 2.9 Hz), 7.3 to 7.4 (m, 2H), 9.35 (broad s, 1H) • 13C NMR (CDCI3) : 55.76, 56.45, 107.30, 107.71, 112.00, 112.26, 114.70, 117.53, 130.78, 132.60, 134.09, 145.98, 147.71, 153.75, 172.95 • IR (CHCI3) : 3327, 1685 cm"1 2) Synthesis of 2-(2,5-dimethoxyphenylamino)aceto-phenone (Compound 5) 16 ml of MeLi (1.4 M/Et20) are added at 0°C and under N2 to a mixture of N-(2,5-dimethoxyphenyl)anthranilic acid (2 g, 73 mmol) in 14 ml of THF. After raising the temperature, the medium is refluxed for 2 hours, 100 ml of water are then added and the mixture is extracted 30 with ether (3 x 100 ml) . After drying over MgS04, the solvent is evaporated off on a rotary evaporator to give the expected derivative in the form of a yellow solid (1.49 g) .
• Yield = 75% • Melting point = 79°C • 1H NMR (CDCI3) : 2.64 (s, 3H) , 3.76 (s, 3H) , 3.84 (s, 3H) , 6.55 (dd, 1H, J = 8.8 and 2.9 Hz), 6.73 (dd, 1H, J = 1.4 and 7.5 Hz), 6.85 (d, 1H, J = 8.8 Hz), 7.04 (d, 1H, J = 2.9 Hz), 7.3 to 7.4 (m, 2H), 7.81 (dd, 1H, J = 1.5 and 8.0 Hz), 10.5 (broad s, 1H). • 13C NMR (CDC13) : 48.15, 55.73, 56.36, 107.10, 107.72, 112.05, 114.80, 116.84, 120.09, 130.68, 132.42, 134.35, 145.98, 146.67, 153.62, 201.00 • IR (CHCI3) : 3350, 1642 cm"1 3) Synthesis of 1,4-dimethoxy-9-methylacridine (Compound 6) A mixture of 2-(2,5-dimethoxyphenylamino)acetophenone (1.3 g, 48 mmol) and polyphosphoric acid (13 g, 133 mmol) is heated at 100°C for 1 hour. After addition of 50 ml of water, the mixture is neutralized with 4M sodium hydroxide and then extracted with CHC13 (3 x 100 ml) . After drying over MgSC>4 and evaporating off the solvent, the crude product obtained is purified by filtration through silica (CH2CI2) to give the expected tricyclic derivative quantitatively in the form of a brown-orange solid.
• Melting point = 136°C • 1H NMR (CDCI3) : 3.36 (s, 3H) , 3.96 (s, 3H), 4.09 (s, 3H) , 6.68 (d, 1H, J = 8.0 Hz), 6.89 (d, 1H, J = 8.4 Hz), 7.54 (m, 1H) , 7.73 (m, 1H) , 8.32 (d, 1H, J = 8.4), 8.36 (d, 1H, J = 8.8 Hz) • 13C NMR (CDCI3) : 17.78, 55.66, 56.13, 102.43, 105.18, 120.25, 124.28, 125.62, 126.59, 129.44, 130.81, 142.45, 144.23, 147.21, 149.46, 151.45 • IR (CHCI3) : 1685, 1661 cm"1 4) Synthesis of 9-methylacridine-l,4-dione (Compound 7) A solution of 1,4-dimethoxy-9-methylacridine (20 mg, 0.079 mmol) and cerium ammonium nitrate (196 mg, 0.357 mmol) in a CH2CI2/H2O mixture (0.5 ml/0.25 ml) is stirred at 0°C for 20 minutes. After adding 1.4 ml of H20 and 0.4 ml of saturated NaHC03 solution, the medium is left stirring and is then extracted with CH2CI2 (3 x 3 ml) . The organic phases are dried over MgSC>4 • After evaporating off the solvent on a rotary evaporator, the expected quinone is obtained in the form of a brown powder (15 mg).
• Yield = 90% • Melting point = > 260°C • aH NMR (CDC13) : 3.22 (s, 3H) , 7.09 (d, 1H, J = .3 Hz), 7.18 (d, 1H, J = 10.3 Hz), 7.78 (dd, 1H, J = 8.5 and 8.5 Hz), 7.91 (dd, 1H, 8.5 and 8.5 Hz), 8.32 (d, 1H, J = 8.5), 8.43 (d, 1H, J = 8.5 Hz). • 13C NMR (CDCI3) : 15.87, 124.40, 125.41, 126.30, 10 129.61, 132.32, 132.52, 137.88, 141.61, 147.05, 148.23, 151.23, 183.43, 186.69 • IR (CHCI3) : 1701, 1661 cm-1 D - Preparation of the intermediate products of formula IVa (Scheme II) D-l - Synthesis of 6-methyl-l,11-diazanaphthacene-5,12-dione (Intermediate Di) A solution of 9-methylacridine-l,4-dione (200 mg, 0.896 mmol), acrolein-N,N-dimethylhydrazone (96 mg, 0.984 mmol) and acetic anhydride (1 ml) in 20 ml of CH2CI2 is stirred under N2 at room temperature for 30 minutes. After concentrating the solvent, the medium is 25 purified by filtration through silica (CH2CI2) to recover the addition product that is not completely aromatic. A suspension of this compound and of 10% Pd/C (20 mg) in 4 ml of toluene is refluxed for 30 minutes. After concentrating, the crude product obtained is 30 purified by flash chromatography on silica (98/2 CH2Cl2/MeOH) to give the expected tetracycle in the form of a beige-colored powder (23 mg).
• Yield = 13% • XH NMR (CDCI3) : 3.32 (s, 3H) , 7.78-7.83 (m, 2H) , 35 7.95 (ddd, 1H, J = 8.4, 7.7 and 1.5 Hz), 8.39 (dd, 1H, J =8.8 and 1.5 Hz), 8.51 (dd, 1H, J = 7.7 and 1.5 Hz), 8.68 (dd, 1H, J = 8.1 and 1.9 Hz), 9.16 (dd, 1H, J = 4 . 8 and 1.9 Hz) • 13C NMR (CDCI3) : 16.67, 124.59, 125.44, 128.39, 129.76, 129.89, 132.25, 132.54, 132.88, 135.93, 148.00, 148.59, 148.73, 152.48, 155.31, 180.81, 184.37 • IR (CHCI3) : 1703, 1663 cm"1 D-2 - Syntheasis of 3-methoxy-6-methyl-l,ll-diazanaphthacene-5 , 12-dione (Intermediate D2) 3-Methoxy-6-methyl-l,ll-diazanaphthacene-5,12-dione is prepared according to the procedure described in D-l, 10 starting with a solution of 9-methylacridine-l,4-dione (Compound 7) (200 mg, 0.896 mmol),2-methoxy-2-propenal-dimethylhydrazone (126 mg, 0.984 mmol) and acetic anhydride (1 ml) in 20 ml of CH2C12.
EXAMPLE 1 -Methyl-9ff-quino [4 , 3,2-de] [1,10]phenanthrolin-9-one (CRL 8323) A solution of the intermediate tetracycle Bi (1 g, 3.47 mmol) and of dimethylformamide diethyl acetal 20 (2 ml, 10.41 mmol) in 7 ml of DMF is refluxed for 1 hour. After evaporating to dryness, ammonium chloride (2.77 g, 52 mmol) and 50 ml of ethanol are added. The reaction medium is refluxed again for 30 minutes. After evaporating off the solvent, the crude product is taken 25 up in water and extracted 4 times with dichloromethane. The organic phases are dried over MgSCU and then evaporated. After recrystallization from 125 ml of methanol, 0.7 g of the expected compound CRL 8323 is obtained in the form of a mustard-yellow solid. 30 • Yield = 67% • Melting point = 200°C • XH NMR (CDCI3) : 2.69 (s, 3H) , 7.65 (dd, 1H, J = 8 and 4.8 Hz), 7.81 (dd, 1H, J = 8 and 1.2 Hz), 8.44 (d, 1H, J = 1.2 Hz), 8.49 (d, 1H, J = 8 Hz), 8.50 (d, 1H, J = 5.6 Hz), 8.78 (dd, 1H, J = 2 and 8 Hz), 9.15 (dd, 1H, J = 4.8 and 2 Hz), 9.24 (d, 1H, J = 5.6 Hz) • 13C NMR (CDCI3) : 22.06, 116.54, 117.87, 122.15, 123.12, 125.24, 128.74, 132.58, 133.47, 136.25, 137.19, 141.63, 143.88, 144.79, 149.16, 149.31, 152.09, 155.15, 181.53 • MS (m/z) : 297 (17.6), 296 (34.3), 268 (25.4), 149 (50.3) EXAMPLE 2 -Chloro-9tf-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8301) Preparation according to the process described in 10 Example 1, starting with the intermediate tetracycle B2 (0.25 g, 0.81 mmol) and dimethylformamide diethyl acetal (1.5 ml, 8.75 mmol) in DMF (4.5 ml). Ammonium chloride (2.95 g, 55 mmol), ethanol (50 ml). After purification by flash chromatography (98/2 CH2Cl2/MeOH), 15 60 mg of the expected compound CRL 8301 are obtained in the form of a yellow solid.
• Yield = 23% • Melting point = 200°C • XH NMR (CDC13) : 7.68 (dd, 1H, J = 8.4 and 20 4.8 Hz), 7.94 (dd, 1H, J = 8.8 and 2 Hz), 8.46 (d, 1H, J = 5.6 Hz), 8.55 (d, 1H, J = 8.8 Hz), 8.63 (d, 1H, J = 2 Hz), 8.79 (dd, 1H, J = 2 and 8.4 Hz), 9.18 (dd, 1H, J = 4.8 and 2 Hz), 9.30 (d, 1H, J = 5.6 Hz) • 13C NMR (CDCI3) : 117.07, 118.46, 122.98, 124.82, 25 126.12, 129.34, 133.02, 134.81, 137.00, 137.42, 137.79, 144.45, 146.35, 150.24, 150.45, 152.55, 156.02, 181.9 • MS (m/z): 319 (43), 317 (100), 291 (14.5), 290 (18), 289 (100).
EXAMPLE 3 - (Benzylamino) -9JJ-qui.no [4 ,3,2-de] [1,10]phenanthrolin-9-one (CRL 8241) Preparation according to the process described in Example 1, starting with the intermediate tetracycle B3 35 (3.58 g, 9.45 mmol) and dimethylformamide diethyl acetal (5.7 ml, 33.26 mmol) in DMF (19 ml). Ammonium chloride (2.95 g, 55 mmol), ethanol (50 ml). After purification by flash chromatography (96/4 CH2Cl2/MeOH), 2 g of the expected compound CRL 8241 are obtained in the form of a wine-colored powder.
• Yield = 55% • Melting point = 219°C • XH NMR (CDC13) : 4.61 (d, 2H) , 5.10 (t, 1H) , 7.31 (dd, 1H, J = 8.8 Hz, J = 2.4 Hz), 7.452-7.327 (m, 5H) , 7.55 (d, 1H, J = 2.4 Hz), 7.63 (dd, 1H, J = 4.4 Hz, J = 8.4 Hz), 8.29 (d, 1H, J = 5.2 Hz), 8.36 (d, 1H, J = 8.8 Hz), 8.79 (dd, 1H, J = 1.2 Hz, J = 8.4 Hz), 9.13 10 (dd, 1H, J = 4.4 and 1.2 Hz), 9.14 (d, 1H, J = 5.2 Hz) • MS (m/z): 388 (7), 387 (100), 386 (85), 385 (25), 369 (99), 368 (44) EXAMPLE 4 5-(Dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8325) Preparation according to the process described in Example 1, starting with the intermediate tetracycle B5 (0.25 g, 0.79 mmol) and dimethylformamide diethyl 20 acetal (0.5 ml, 2.98 mmol) in DMF (5 ml). Ammonium chloride (1 g, 18.7 mmol), ethanol (16 ml) . After purification by flash chromatography (100/5 CH2Cl2/MeOH) , 170 mg of the expected compound CRL 8325 are obtained in the form of a violet powder. 25 • Yield = 66% • Melting point = > 260°C • XH NMR (CDCI3) : 3.25 (s, 6H) , 7.45 (dd, 1H, J = 9.2 Hz, J = 3 Hz), 7.57 (d, 1H, J = 3 Hz), 7.63 (dd, 1H, J = 4.4 and 8 Hz), 8.41 (d, 1H, J = 9.2 Hz), 8.43 (d, 1H, J = 5.6 Hz), 8.81 (dd, 1H, J = 2 and 7.6 Hz), 9.13 (dd, 1H, J = 4.4 and 2 Hz), 9.17 (d, 1H, J = 5.6 Hz) • 13C NMR (CDCI3) : 40.45, 100.84, 116.81, 118.69, 118.99, 125.19, 126.10, 129.46, 134.62, 136.03, 136.30, 139.00, 140.69, 148.16, 149.15, 151.53, 152.47, 154.83, 181.65 • MS (m/z): 326 (34.5), 325 (100), 324 (100), 254 (15.5), 253 (13.4).
EXAMPLE 5 -Methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8297) Preparation according to the process described in 5 Example 1, starting with the intermediate tetracycle B6 (2 g, 6.57 mmol) and dimethylformamide diethyl acetal (4 ml, 23.34 mmol) in DMF (14 ml) . Ammonium chloride (8 g, 149.5 mmol), ethanol (130 ml). After purification by flash chromatography (100/5 CH2Cl2/MeOH) , 170 mg of 10 the expected compound CRL 8297 are obtained in the form of a greenish solid.
• Yield = 66% • Melting point = > 260°C • XH NMR (CDC13) : 4.10 (s, 3H) , 7.62 (dd, 1H, J = 15 9.2 Hz, J = 2.4 Hz), 7.66 (dd, 1H, J = 4.4 and 8 Hz), 7.96 (d, 1H, J = 2.4 Hz), 8.48 (d, 1H, J = 2.4 Hz), 8.54 (d, 1H, J = 9.2 Hz), 8.80 (dd, 1H, J = 2.4 and 8 Hz), 9.16 (dd, 1H, J = 4.4 and 2.4 Hz), 9.25 (d, 1H, J = 5.2 Hz) • 13C NMR (CDCI3) : 30.93, 116.86, 118.41, 122.44, 125.56, 129.25, 134.96, 136.55, 137.13, 141.52, 143.67, 149.11, 149.77, 152.37, 155.38, 161.71, 181.93, 207.00 • MS (m/z): 313 (26), 312 (100), 285 (2), 284 (15), 269 (15), 242 (32.5).
EXAMPLE 6 7-Nitro-9Jf-quino [4,3,2-de] [1,10]phenanthrolin-9-one (CRL 8289) Ascididemin (2 g, 7.06 mmol) is added portionwise to a 30 mixture of 45 ml of sulfuric acid and 45 ml of nitric acid at 0°C. The reaction medium is heated at 130°C for 2 hours and, after cooling, is then poured into a conical flask containing 400 g of ice. After filtration, a yellow precipitate is obtained, which is 35 rinsed several times with ether. It is then taken up in a 600/1/300 CH2CI2/NH4OH/H2O mixture. The organic phase is recovered and the aqueous phase is extracted 3 times with CH2CI2. After drying over MgS04, the organic phases are evaporated to give 1.62 g of the expected compound CRL 8289 in the form of a yellow solid.
• Yield = 70% • Melting point = 224°C • :H NMR (CDC13) : 7.69 (dd, 1H, J = 4.4 and 8 Hz), 8.04 (dd, 1H, J = 8 and 8 Hz), 8.28 (dd, 1H, J = 8 Hz), 8.56 (d, 1H, J = 5.2 Hz), 8.75 (dd, 1H, J = 2 and 8 Hz), 8.89 (dd, 1H, J = 1.2 and 8 Hz), 9.18 (dd, 1H, J = 4.4 and 2 Hz), 9.37 (d, 1H, J = 5.6 Hz) 10 • 13C NMR (CDCI3) : 79.20, 117.61, 118.39, 124.21, 124.89, 125.98, 127.54, 129.04, 130.14, 135.62, 136.63, 148.17, 149.76, 149.94, 150.12, 151.66, 154.88, 180.56.
• MS (m/z): 328 (18), 327 (100). 299 (22), 297 (9), 269 (10), 253 (24), 242 (11), 241 (33).
EXAMPLE 7 7-Amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8344) A suspension of the nitro derivative CRL 8289 (0.4 g, 20 1.22 mmol) and iron (0.37 g, 6.59 mmol) in a 10/10 ACOH/H2O mixture is refluxed for 1 hour. EDTA (1.94 g, 6.59 mmol) is added and the reaction medium is then basified with concentrated sodium hydroxide. The mixture is extracted 3 times with CH2CI2. After drying 25 over MgSC>4, the organic phases are evaporated to give 0.32 g of the expected compound CRL 8344 in the form of a blue solid.
• Yield = 88% • Melting point = > 260°C • XH NMR (CDCI3) : 5.68 (s, 2H) , 7.16 (d, 1H, J = 7.8 Hz), 7.66 (dd, 1H, J = 7.6 and 4.8 Hz), 7.69 (dd, 1H, J = 7.8 and 7.8 Hz), 7.91 (d, 1H, J = 7.8 Hz), 8.46 (d, 1H, J = 5.2 Hz), 8.77 (dd, 1H, J = 1.6 and 7.6 Hz), 9.17 (dd, 1H, J = 1.6 and 4.8 Hz), 9.21 (d, 1H, J = 35 5.2 Hz). • 13C NMR (CDC13) : 109.42, 112.71, 117.70, 118.43, 124.29, 125.64, 129.12, 132.63, 132.81, 135.53, 137.27, 141.68, 148.68, 148.89, 149.03, 151.96, 154.68, 180.71 • MS (m/z): 298 (34.7), 297 (100), 269 (11), 268 (8) .
EXAMPLE 8 5-Bromo-9if-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8248) A solution of bromine (0.2 ml, 3.88 mmol) in 5 ml of acetic acid is added dropwise to a solution of ascididemin (0.5 g, 1.77 mmol) in 20 ml of acetic acid. 10 The reaction medium is refluxed (stoppered condensor) for 24 hours. After cooling, the mixture is neutralized with saturated NaHC03 solution and extracted 4 times with CH2C12. The organic phases are dried over MgS04 and then evaporated. The crude product obtained is purified 15 by flash chromatography on a column of silica (96/4 CH2Cl2/MeOH) to give 0.548 g of the expected compound CRL 8248 in the form of a yellow solid.
• Yield = 86% • Melting point = 208°C • 1E NMR (CDC13) : 7.68 (dd, 1H, J = 4.4 and 8 Hz), 8.09 (dd, 1H, J = 8.8 Hz, J = 2 Hz), 8.48 (d, 1H, J = 8.8 Hz), 8.49 (d, 1H, J = 6 Hz), 8.79 (dd, 1H, J = 2 and 8 Hz), 8.82 (d, 1H, J = 2 Hz), 9.18 (dd, 1H, J = 2 Hz, J = 4.4 Hz), 9.30 (d, 1H, J = 6 Hz) 25 • 13C NMR (CDCI3) : 116.76, 117.04, 118.26, 124.76, 125.81, 125.93, 129.05, 134.52, 135.43, 136.72, 137.01, 144.41, 146.24, 149.93, 150.12, 152.27, 155.67, 181.69 • MS (m/z): 363 (99), 362 (83), 361 (100), 360 (27), 255 (9), 254 (51) .
EXAMPLE 9 -Amino-9H-quino[4,3,2-de] [1,10]phenanthrolin-9-one (CRL 8347) Sodium azide (2.34 g, 36.1 mmol) is added to a solution 35 of bromo ascididemin: CRL 8248 (2.3 g, 6.33 mmol) in 4 60 ml of DMF. The reaction medium is refluxed for 4 hours. After cooling, the mixture is evaporated to dryness and the solid obtained is taken up in water. This mixture is extracted 4 times with CH2CI2. After drying over MgSCU and evaporating off the solvent, the crude product is purified by flash chromatography on a column of silica (90/10 HCCl3/MeOH) to give 115 mg of the expected compound CRL 8347 in the form of a black 5 powder.
• Yield = 6% • Melting point = > 260°C • XH NMR (CDC13) : 7.43 (dd, 1H, J = 8.8 and 2.4 Hz), 7.74 (dd, 1H, J = 4.8 and 8 Hz), 7.81 (d, 1H, J = 2.4 Hz), 8.48 (d, 1H, J = 6 Hz), 8.50 (d, 1H, J = 8.8 Hz), 8.90 (dd, 1H, J = 2 and 8 Hz), 9.25 (dd, 1H, J = 2 and 4.8 Hz), 9.29 (d, 1H, J = 6 Hz) • 13C NMR (DMSO): 102.26, 117.13, 118.54, 121.62, 123.20, 125.34, 126.11, 129.18, 133.80, 134.83, 135.47, 138.42, 147.65, 148.29, 151.63, 152.39, 154.32, 180.35 • MS (m/z): 298 (32), 297 (100), 269 (4), 268 (0.5) EXAMPLE 10 10-Methoxy-9J?-quino[4,3,2-de] [1,10]phenanthrolin-9-one (CRL 8368) Preparation according to the procedure described by Y. Kitahara et al., Heterocycles, 1993, 36, 943-946.
EXAMPLE 11 -Hydroxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8387) Preparation according to the procedure described by Y. Kitahara et al., Tetrahedron, 1997, 53, 17029-17038.
EXAMPLE 12 9ff-Quino [4,3,2-de] [1,10]phenanthrolin-9-imine (CRL 8290) 100 mg (0.353 mmol) of ascididemin are dissolved in a 35 solution containing 5 ml of aqueous ammonia and 2 ml of EtOH. The reaction medium is refluxed (stoppered condensor) for 72 hours. After evaporating off the solvent on a rotary evaporator, the residue is purified by flash chromatography on alumina (99/1 CH2Cl2/MeOH) to give 87 mg of compound CRL 82 90.
• Yield = 87% • Melting point = > 260°C • 1E NMR (CDC13) : 7.61 (dd, 1H, J = 5 and 8 Hz), 7.86 (dd, 1H, J = 8 and 8 Hz), 7.97 (dd, 1H, J = 8 and 8 Hz), 8.40 (d, 1H, J = 8 Hz), 8.43 (d, 1H, J = 6 Hz), 8.64 (d, 1H, J = 8 Hz), 9.04 (dd, 1H, J = 8 and 2.5 Hz), 9.08 (dd, 1H, J = 5 and 2.5 Hz), 9.22 (d, 1H, 10 J = 6 Hz), 12.48 (s, 1H) EXAMPLE 13 9H-Quino[4,3,2-de][1,10]phenanthrolin-9-oxime (CRL 8292) 500 mg (1.77 mmol) of ascididemin and 500 mg of NH2OH, 1/2 H2S04 are dissolved in 1 ml of pyridine and 10 ml of EtOH. The reaction medium is refluxed for 48 hours. After evaporating off the solvent on a rotary evaporator, 20 ml of water are added and the medium is 20 extracted with HCC13 (3 x 20 ml) . The organic phases are dried over MgS04 and then evaporated on a rotary evaporator. The residue is purified by flash chromatography on alumina (99/1 CH2Cl2/MeOH) to give 240 mg of the oxime CRL 8292 in the form of a yellow 25 powder.
• Yield = 46% • Melting point = > 260°C • XH NMR (CDCI3) : 7.68 (dd, 1H, J = 4.4 and 8.4 Hz), 7.98 (ddd, 1H, J = 7.6 and 7.6 and 1.6 Hz), 8.07 (ddd, 1H, J = 7.6 and 7.6 and 1.6 Hz), 8.30 (dd, 1H, J = 7.6 and 1.6 Hz), 8.56 (d, 1H, J = 6 Hz), 8.75 (dd, 1H, J = 7.6 and 1.6 Hz), 9.00 (dd, 1H, J = 8.4 and 1.2 Hz), 9.12 (dd, 1H, J = 4.4 and 1.2 Hz), 9.41 (d, 1H, J = 6 Hz) • 13C NMR (CDCI3) : 115.06, 116.14, 123.16, 123.29, 125.46, 128.33, 128.77, 129.54, 131.86, 132.16, 138.48, 140.94, 141.37, 145.82, 146.75, 151.27, 151.65, 151.80 •MS (m/z): 298 (64.5), 268 (100), 266 (21.9) EXAMPLE 14 -(2-Acetylanilino)-9ff-quino[4,3,2-de] [1,10]phenanthrolin-9-one (CRL 8333) Preparation according to the process described in Example 1, starting with the intermediate tetracycle B7 (0.4 g, 0.98 mmol) and dimethylformamide diethyl acetal (0.6 ml, 3.4 3 mmol) in DMF (4 ml) . Ammonium chloride (1.2 g, 22.4 mmol), ethanol (20 ml). After purification 10 by flash chromatography (100/5 CH2Cl2/MeOH) , 144 mg of the expected compound CRL 8333 are obtained in the form of a brown-red solid.
• Yield = 35% • Melting point = > 260°C • XH NMR (CDCI3) : 2.88 (s, 3H) , 3.12 (s, 3H) , 5.54 (d, 1H), 7.13 (d, 1H, J = 6 Hz), 7.30 (ddd, 1H, J = 7.6 and 7.6 and 1.2 Hz), 7.45 (ddd, 1H, J = 7.6 and 7.6 and 1.2 Hz), 7.51 (d, 1H, J = 7.6 Hz), 7.65 (broad s, 1H), 7.69 (d, 1H, J = 7.6 Hz), 7.88 (ddd, 1H, J = 7.6 and 20 7.6 and 1.2 Hz), 7.96 (ddd, 1H, J = 7.6 and 7.6 and 1.2 Hz), 8.48 (d, 1H, J = 6 Hz), 8.51 (d, 1H, J = 6 Hz), 8.57 (dd, 1H, J = 7.6 and 1.2 Hz), 8.64 (dd, 1H, J = 7.6 and 1.2 Hz), 9.23 (d, 1H, J = 6 Hz) • 13C NMR (CDCI3) : 37.22, 45.05, 109.94, 113.94, 25 116.56, 117.38, 122.92, 123.34, 125.43, 125.90, 129.47, 130.27, 131.61, 132.94, 135.87, 137.17, 137.57, 145.87, 146.93, 149.81, 150.28, 153.30, 154.27, 154.54, 154.61, 183.73 EXAMPLE 15 -Hydroxy-9ff-quino[4,3,2-de][1,10]phenanthrolin-9-one diiodide (CRL 8369) 500 mg (1.597 mmol) of the compound of Example 10 35 (CRL 8368) and 40 ml of acetic acid in 100 ml of hydriodic acid (57%) are heated at 100°C for 30 minutes. After cooling, the reaction medium is poured into 500 ml of water and ice is added, followed by neutralization with NaHCC>3 (solid) . After several extractions with a mixture of 5% MeOH in HCC13 (6 times 500 ml) , the organic phases are dried over MgS04 and then concentrated on a rotary evaporator to give 0.36 g of compound CRL 8369 in the form of a wine-colored 5 powder.
• Yield = 41% • Melting point = > 260°C • XH NMR (DMSO) : 6.24 (d, 1H, J = 7.6 Hz), 6.86 (td, 1H, J = 8 and 4 Hz), 7.27 (d, 2H, J = 4 Hz), 7.57 (d, 1H, J = 5.2 Hz), 7.89 (d, 1H, J = 8 Hz), 7.93 (dd, 1H, J = 7.6 and 7.6 Hz), 8.51 (d, 1H, J = 5.2 Hz), 9.54 (s, 1H), 12.62 (broad m, 1H), 14.42 (s, 1H) • 13C NMR (DMSO): 107.81, 109.87, 114.24, 115.36, 116.31, 117.33, 120.11, 120.97, 124.14, 127.63, 132.18, 132.81, 134.89, 139.24, 139.35, 141.15, 148.72, 181.29 EXAMPLE 16 -Chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8373) 50 mg (0.09 mmol) of the salt of Example 15 (CRL 8369) dissolved in 4 ml of POCI3 are refluxed for 2 hours. After evaporating off the POCI3 on a rotary evaporator, the reaction medium is neutralized with saturated NaHC03 solution. After several extractions with a 25 mixture of 5% MeOH in HCC13 (5 times 20 ml), the organic phases are dried over MgS04 and then concentrated on a rotary evaporator. The residue obtained is purified by flash chromatography on a column of silica (95/5 CH2Cl2/MeOH) to give 20 mg of the 30 expected compound CRL 8373 in the form of a yellow powder.
• Yield = 77% • Melting point = > 260°C • XH NMR (CDCI3) : 7.67 (d, 1H, J = 5.6 Hz), 7.95 35 (ddd, 1H, J = 8 and 8 and 0.8 Hz), 8.03 (ddd, 1H, J = 8 and 8 and 1.2 Hz), 8.57 (d, 1H, J = 5.6 Hz), 8.61 (ddd, 1H, J = 8 and 1.2 Hz), 8.68 (ddd, 1H, J = 8 and 0.8 Hz), 8.97 (d, 1H, J = 5.6 Hz), 9.30 (d, 1H, J = 5.6 Hz) • 13C NMR (CDCI3) : 117.60, 117.84, 123.31, 123.60, 126.69, 129.10, 131.17, 132.38, 133.47, 138.21, 146.24, 146.51, 147.26, 149.40, 150.32, 154.30, 154.94, 180.47 •MS (m/z): 318 (9.6), 316 (70.2), 290 (29.6), 288 5 (100), 255 (23.4), 253 (26.8).
EXAMPLE 17 -Bromo-10-methoxy-9J?-quino[4 ,3,2-de] [1,10]phenanthrolin 9-one 10 (CRL 8389) Preparation according to the process described in Example 1, starting with the intermediate tetracycle Bs (0.74 g, 1.93 mmol) and dimethylformamide diethyl acetal (1.3 ml, 7.24 mmol) in 15 ml of DMF. Ammonium 15 chloride (1.96 g, 36.4 mmol), ethanol (200 ml). After purification by flash chromatography (95/5 CH2Cl2/MeOH), 210 mg of the expected compound CRL 8389 are obtained in the form of an orange powder.
• Yield = 42% • Melting point = > 260°C • 1H NMR (CDCI3) : 4.14 (s, 3H) , 7.14 (d, 1H, J = 5.6 Hz), 8.05 (dd, 1H, J = 2 and 8.8 Hz), 8.43 (d, 1H, J = 6 Hz), 8.44 (d, 1H, J = 8.8 Hz), 8.76 (d, 1H, J = 2 Hz), 8.95 (d, 1H, J = 6 Hz), 9.27 (d, 1H, J = 5.6 Hz) • 13C NMR (CDCI3) : 57.12, 109.52, 117.00, 117.76, 119.46, 121.58, 124.81, 125.52, 134.72, 135.49, 137.00, 144.85, 146.51, 147.24, 147.92, 150.43, 156.21, 167.98, 180.57 • MS (m/z): 393 (100), 392 (61.7), 391 (99.2), 390 (17.4), 362 (9.2), 333 (9.8), 254 (34.5).
EXAMPLE 18 -Amino-ll-methoxy-9if-quino [4 ,3,2-de] [1,10]phenanthrolin 35 9-one (CRL 8389) A solution of compound CRL 8389 (0.5 g, 1.3 mmol) and NaN3 (0.5 g, 7.7 mmol) in 20 ml of DMF is heated at 90°C for 10 hours. After concentrating, the residue is taken up in IN KOH (35 ml) and then extracted with 95/5 CH2Cl2/MeOH (4 x 200 ml) . After drying over MgSCU and concentrating on a rotary evaporator, the crude product obtained is purified by flash chromatography on silica 5 (80/20 CH2Cl2/MeOH) to give the expected compound CRL 8389 in the form of a violet powder (65 mg).
• Yield = 15% • Melting point = > 260°C • XH NMR (DMSO-d6) ) : 4.07 (s, 3H) , 6.62 (s, 2H) , 10 7.36 (d, 1H, J = 8.8 Hz), 7.41 (d, 1H, J = 5.9 Hz), 7.74 (s, 1H) , 8.08 (d, 1H, J = 8.8 Hz), 8.48 (d, 1H, J = 5.2 Hz), 8.86 (d, 1H, J = 5.9 Hz), 9.08 (d, 1H, J = 5.2 Hz) • IR (KBr) : 3420, 3196, 1636, 1616 cm"1 EXAMPLE 19 -Amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one hydrochloride (CRL 8406) A solution of 5-amino-9H-quino[4,3,2-de] [1,10]phenan-throlin-9-one (1 g, 3.35 mmol) and concentrated HC1 (0.56 ml) in 200 ml of methanol is heated at room temperature for 1 hour. 200 ml of ether are added and, after leaving the salt to precipitate out, the medium is filtered to recover the expected compound CRL 8406 in the form of a black powder (1 g).
• Yield = 90% • 1H NMR (DMSO-de) : 7.44 (dd, 1H, J = 8.8 and 2.2 Hz), 7.81 (d, 1H, J = 2.2 Hz), 7.93 (dd, 1H, J = 5.6 and 5.9 Hz), 8.12 (d, 1H, J = 8.8 Hz), 8.66 (d, 1H, J = 5.6 Hz), 8.75 (d, 1H, J = 5.9 Hz), 9.07 (d, 1H, J = 5.9 Hz), 9.14 (d, 1H, J = 5.9 Hz) • IR (KBr) : 3404, 3287, 3170, 1691, 1676, 1649 cm"1 EXAMPLE 20 - (Dimethylamino) -9ff-quino [4 ,3,2-de] [1,10]phenanthrolin-9-one hydrochloride (CRL 8407) A solution of 5-(dimethylamino)-9H-quino[4,3, 2-de]-[1,10]phenanthrolin-9-one (1 g, 3.06 mmol) and concentrated HC1 (0.3 ml) in 120 ml of CHCI3 is stirred at room temperature for 45 minutes. After addition of 350 ml of ether, followed by precipitation of the salt, the medium is filtered to recover the expected product 5 in the form of a navy blue powder (0.97 g).
• Yield = 87% • Melting point = > 260°C EXAMPLE 21 5- (Benzylamino)-9Jf-qui.no [4 ,3,2-de] [1,10]phenanthrolin-9-one hydrochloride (CRL 8416) A solution of 5-(benzylamino)-9H-quino[4, 3, 2-de] [1,10]-phenanthrolin-9-one ASC20 (0.94 g, 2.42 mmol) and concentrated HC1 (0.2 ml) in 40 ml of CHCI3 is stirred 15 at room temperature for 30 minutes. The solvent is evaporated off and 150 ml of ether are added and, after leaving the salt to precipitate out, the medium is filtered to recover the expected compound CRL 8416 in the form of a black powder (0.98 g).
• Yield = 95% • Melting point = > 260°C EXAMPLE 22 -(Dimethylamino-2-ethyl)amino-9ff-quino[4,3,2-de]-25 [1/10]phenanthrolin-9-one (CRL 8419) ml (166 mmol) of trifluoroacetic acid are added to a mixture of compound CRL 8347 (2.56 g, 8.59 mmol) and dimethylformamide diethyl acetal (7.9 ml, 43.3 mmol) at 0°C. The reaction medium is stirred for 5 minutes and 30 sodium cyanoborohydride (8.2 g, 130 mmol) is then added portionwise. The reaction medium is then heated and maintained at 95°C. After 18 hours, the mixture is basified to pH 8 with saturated NaHCC>3 solution (about 600 ml) and then extracted with 95/5 CHCl3/MeOH 35 (3 x 800 ml) . The organic phases are washed with water and then dried over MgSC>4. After evaporating off the solvent on a rotary evaporator, the crude product obtained is purified by filtration through alumina (CHCI3 and then 95 CHCl3/MeOH) to give 1.15 g of the expected compound CRL 8419 in the form of a black powder.
• Yield = 36% • Melting point: decomposes before melting • 1H NMR (CDC13) : 2.37 (s, 6H) , 2.62 (t, 2H, J = 7.32 Hz), 3.70 (t, 2H, J = 7.32 Hz), 7.39 (dd, 1H, J = 9.2 and 3 Hz), 7.62 (dd, 1H, J = 8.0 and 4.5 Hz), 7.66 (d, 1H, J = 3 Hz), 8.35 (d, 1H, J = 9.2 Hz), 8.38 (d, 1H, J = 5.7 Hz), 8.79 (dd, 1H, J = 8.0 and 1.8 Hz), 10 9.12 (dd, 1H, J = 4.5 and 1.8 Hz), 9.15 (d, 1H, J = 5.7 Hz) 13 C NMR (CDCI3) : 45.97, 50.31, 56.40, 101.05, 116.81, 118.48, 118.89, 125.22, 126.30, 129.35, 134.87, 135.97, 136.32, 138.91, 140.55, 148.25, 148.98, 149.69, 15 152.23, 154.82, 181.37 • IR (CHC13) : 1663 cm"1 •MS (m/z): 369 (100), 354 (15), 236 (37) EXAMPLE 23 5-(Dimethylamino-2-ethyl)amino-9H-quino[4,3,2- de] [1 , 10] phenanthrolin- 9-one hydrochloride (CRL 8418) 265 (j.1 (3.25 mmol) of concentrated hydrochloric acid are added to 1.2 g (3.25 mmol) of compound CRL 8419 dissolved in 60 ml of chloroform. The reaction medium 25 is stirred for 2 hours at room temperature. The precipitate formed is filtered off and then washed with ether. Compound CRL 8418 (0.93 g) is obtained in the form of a black powder.
• Yield = 70% • 1H NMR (DMSO-dg) : 2.67 (s, 6H) , 3.09 (m, 2H) , 4.01 (m, 2H) , 7.67 (dm, 1H, J = 9.2 Hz), 7.80 (dd, 1H, J = 8,0 and 4.5 Hz), 7.94 (m, 1H) , 8.26 (d, 1H, J = 9.2 Hz), 8.64 (d, 1H, J = 5.7 Hz), 9.09 (m, 1H) , 9.12 (dd, 1H, J = 4.5 and 1.8 Hz), 9.14 (d, 1H, J = 5.7 Hz).
EXAMPLE 24 -Bis(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one (CRL 8422) mmol of sodium cyanoborohydride NaBH3CN (0.63 g) are added portionwise to a solution of 5-amino-9tf-quino-[4,3,2-de][1,10]phenanthrolin-9-one (1 g, 3.95 mmol) and chloroacetaldehyde (50% aqueous, 2.6 ml, 16.8 mmol) 5 in acetic acid (30 ml), at 0°C. The reaction medium is stirred at 0°C for 5 minutes and then at room temperature for 30 minutes. Next, the medium is basified with saturated sodium hydrogen carbonate NaHCC>3 solution and then extracted with a 95/5 10 CHCls/MeOH mixture. The organic phases are dried over magnesium sulfate MgS04 and concentrated on a rotary evaporator. The crude product obtained is purified by filtration through silica (CHCI3 and then 99/1 CHCls/MeOH) to give two compounds: CRL 8422 and 15 CRL 8423 (described in Example 25).
-Bis(chloroethyl)amino-9H-quino[4,3,2-de][1,10]phenan-throlin-9-one (CRL 8422) was obtained in the form of a pink powder (0.14 g): • Yield = 10% • Melting point = 220°C • IR (KBr) : 1666, 1650 cm-1 • XH NMR (CDCI3) : 3.83 (t, 4H, J = 7.0 Hz), 4.04 (t, 4H, J = 7.0 Hz), 7.47 (dd, 1H, J = 9.5 and 2.9 Hz), 7.66 (dd, 1H, J = 8.0 and 4.4 Hz), 7.70 (d, 1H, J = 2.9 Hz), 8.42 (d, 1H, J = 5.6 Hz), 8.50 (d, 1H, J = 9.5 Hz), 8.81 (dd, 1H, J = 8.0 and 1.8 Hz), 9.16 (dd, 1H, J = 4.4 and 1.8 Hz), 9.23 (d, 1H, J = 5.6 Hz) • 13C NMR (CDCI3) : 40.16, 53.60, 101.70, 116.60, 30 118.37, 118.68, 125.39, 125.91, 129.25, 135.13, 136.12, 136.38, 139.42, 141.93, 148.24, 148.73, 149.34, 152.22, 155.08, 181.43.
EXAMPLE 25 5- (2-chloroethyl) amino-9-ff-quino [4 ,3,2-de] [1,10]phenanthrolin-9-one (CRL 8423) According to the process described in Example 24, 0.22 g of compound CRL 8423 are obtained in the form of a violet powder. The characteristics of compound CRL 8423 are as follows: • Yield = 18% • Melting point = 196°C • IR (KBr) : 3413, 3275, 1654, 1617 cm-1 • NMR (CDC13) : 3.81 (t, 2H, J = 5.5 Hz), 3.88 (t, 2H, J = 5.5 Hz), 5.01 (broad s, 1H) , 7.34 (dd, 1H, J = 8.8 and 2.5 Hz), 7.60 (d, 1H, J = 2.5 Hz), 7.65 (dd, 1H, J = 7.5 and 4.4 Hz), 8.41 (d, 1H, J = 5.8 Hz), 8.43 (d, 1H, J = 8.8 Hz), 8.82 (dd, 1H, J = 7.5 and 1.5 Hz), 9.15 (dd, 1H, J = 4.4 and 1.5 Hz), 9.21 (dd, 1H, J = 5.8 Hz) • 13C NMR (CDCI3) : 42.83, 45.01, 100.76, 116.81, 118.78, 120.85, 125.38, 126.35, 129.35, 135.04, 136.04, 136.43, 140.22, 141.56, 148.49 (2C), 149.41, 152.30, 155.07, 181.57.
EXAMPLE 26 12-Methoxy-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one 20 (CRL 8472) 0.54 ml (3 mmol) of dimethylformamide diethyl acetal is added to a suspension of 2-methoxy-ll-methyl-l,6-diazanaphthacene-5,12-dione (Intermediate Bg) (0.23 g, 0.75 mmol) in DMF (7 ml) under N2. The reaction medium 25 is heated at 120°C for 1 hour. After concentrating under vacuum, ethanol (45 ml) and NH4C1 (0.46 g) are added and the mixture is then refluxed for 30 minutes. After concentrating on a rotary evaporator, 30 ml of water are added and the medium is then extracted with 30 CHCl3(2 x 30 ml). The organic phases are dried over MgS04 and concentrated. The crude product obtained is purified by flash chromatography on silica (CHCI3) to give the expected compound CRL 8472 in the form of a brown powder (50 mg).
• Yield = 21% • Melting point = > 260°C • :H NMR (CDCI3) : 4.31 (s, 3H) , 7.04 (d, 1H, J = 8.5 Hz), 7.92 (ddd, 1H, J = 8.1, 7.0 and 1.5 Hz), 8.00 (ddd, 1H, J = 8.4, 7.0 and 1.5 Hz), 8.52 (d, 1H, J = .5 Hz), 8.63 (dd, 1H, J = 8.1 and 1.5 Hz), 8.66 (d, 1H, J = 8.5 Hz), 8.67 (dd, 1H, J = 8.4 and 1.5 Hz), 9.27 (d, 1H, J = 5.5 Hz) • 13C NMR (CDC13) : 54.69, 114.43, 116.75, 118.15, 5 122.92, 123.41, 124.51, 130.62, 131.81, 133.15, 137.86, 139.17, 145.80, 146.28, 149.59, 149.99, 152.24, 167.75, 181.04 • IR (CHCI3) : 1671, 1588 cm"1 • MS (m/z): 313 (50), 312 (91), 284 (17), 283 10 (100), 254 (23), 193 (51).
EXAMPLE 27 4-Bromo-5-amino-9-.ff-quino [4 ,3,2-de] [1,10]phenanthrolin-9-one (CRL 8478) Bromine (35 (0.1, 0.67 mmol) is added to a suspension of compound CRL 8347 (0.2 g, 0.67 mmol) in acetic acid (8 ml) . The reaction medium is heated at 50°C for 6 hours. After concentrating, the medium is basified with 5N sodium hydroxide (20 ml) and then extracted with a 20 5% MeOH/CHCl3 mixture (400 ml) . After drying over MgS04 and evaporating off the solvent, compound CRL 8478 is obtained in the form of a violet powder which is recrystallized from a 20 ml/15 ml CHCl3/pentane mixture (152 mg).
• Yield = 61% • Melting point = > 260°C • XH NMR (DMSO-de) : 7.07 (broad s, 2H) , 7.61 (d, 1H, J = 8.8 Hz), 7.77 (dd, 1H, J = 7.7 and 4.0 Hz), 8.18 (d, 1H, J = 8.8 Hz), 8.61 (d, 1H, J = 7.7 Hz), 9.10 (d, 1H, J = 4.0 Hz), 9.14 (d, 1H, J = 5.9 Hz), 9.91 (d, 1H, J = 5.9 Hz) • IR (CHCI3) : 3501, 3400, 1673 cm-1 • MS (m/z): 378 (42), 377 (100), 376 (48), 375 (27) EXAMPLE 28 ll-Acetoxymethyl-9-H-quino[4,3,2-de] [1,10]phenanthrolin-9-one (CRL 8528) Dimethylformamide diethyl acetal (0.27 ml, 1.5 mmol) is added to a suspension of 3-acetoxymethyl-ll-methyl-l, 6-diazanaphthacene-5,12-dione (Intermediate B10) (0.11 g, 0.31 mmol) in DMF (4 ml) under N2. The reaction medium 5 is heated at 120°C for 1 hour. After concentrating under vacuum, ethanol (25 ml) and NH4C1 (0.23 g) are added and the mixture is then refluxed for 30 minutes. After concentrating on a rotary evaporator, 30 ml of water are added and the medium is then extracted with 10 CHCI3 (2 x 30 ml) . The organic phases are dried over MgS04. After evaporating off the solvent on a rotary evaporator and purification by flash chromatography on silica (CHCI3) , 65 mg of compound CRL 8528 are obtained.
• Yield = 60% • Melting point = 206-210°C • 1ti NMR (CDCI3) : 2.19 (s, 3H) , 5.32 (s, 2H) , 7.96 (ddd, 1H, J = 1, 1.8 and 8 Hz) , 8.03 (ddd, 1H, J = 1, 1.8 and 8.4 Hz), 8.56 (d, 1H, J = 5.5 Hz), 8.64 (dd, 1H, J = 1.1 and 8.4 Hz), 8.71 (dd, 1H, J = 1.1 and 8.0 Hz), 8.77 (d, 1H, J = 2.4 Hz), 9.14 (d, 1H, J = 2.4 Hz), 9.28 (d, 1H, J = 5.5 Hz) • MS (m/z): 355 (88), 313 (100), 296 (25), 267 (7) .
EXAMPLE 29 9-/f-Quino[4,3,2-de] [1,7]phenanthrolin-9-one (CRL 8529) Dimethylformamide diethyl acetal (0.15 ml, 0.875 mmol) is added to a suspension of 6-methyl-l,11-30 diazanaphthacene-5,12-dione (Intermediate Dj) (52 mg, 0.875 ml) under N2. The reaction medium is heated at 120°C for 30 minutes. After concentrating under vacuum, ethanol (60 ml) and NH4C1 (0.34 g) are added and the mixture is refluxed for 30 minutes. After concentrating 35 on a rotary evaporator, 10 ml of water are added and the medium is then extracted with CH2Cl2 (2 x 10 ml) . The organic phases are dried over MgS04 and concentrated. The crude product obtained is purified by flash chromatography on silica (99/1 CH2Cl2/MeOH) to give the expected compound CRL 852 9 in the form of a yellow solid (6 mg).
• Yield = 11% • XH NMR (CDC13) : 7.78 (dd, 1H, J = 8.1 and 5 4.8 Hz), 7.97 (ddd, 1H, J = 8.0, 7.4 and 1.2 Hz), 8.04 (ddd, 1H, J = 8.0, 7.4 and 1.2 Hz), 8.51 (d, 1H, J = 5.9 Hz), 8.69 (dd, 2H, J = 8.0 and 1.5 Hz), 9.08 (dd, 1H, J = 4.8 and 1.9 Hz), 9.13 (d, 1H, J = 5.9 Hz), 9.27 (d, 1H, J = 1.9 and 8.1 Hz) • 13C NMR (CDCI3) : 115.15, 121.76, 122.28, 127.13, 127.16, 129.65, 130.82, 132.21, 132.60, 132.99, 136.88, 139.91, 144.85, 148.00, 148.03, 151.75, 151.84, 179.94 •MS (m/z): 283 (54), 255 (100) 228 (10).
EXAMPLE 30 -Bromo-9-J-f-qui.no[4,3,2-de] [1,7]phenanthrolin-9-one (CRL 8839) Compound CRL 8839 is prepared according to the procedure described in Example 8, starting with 9-H-20 quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8529) (0.5 g, 1.77 mmol); 20 ml of acetic acid; bromine solution (0.2 ml, 3.88 mmol/5 ml of acetic acid); reflux for 24 hours.
EXAMPLE 31 -Amino-9-J?-quino [4 ,3,2-de] [1,7]phenanthrolin-9-one (CRL 8836) Compound CRL 8836 is prepared according to the procedure described in Example 9, starting with 5-30 bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8839) (1.15 g, 18 mmol); 250 ml of DMF; sodium azide (1.2 g, 1.85 mmol); reflux for 4 hours.
EXAMPLE 32 5- (Dimethylamino-2-ethyl) amino-9-J-f-quino [4 ,3,2-de] -[1,7]phenanthrolin-9-one (CRL 8840) Compound CRL 884 0 is prepared according to the procedure described in Example 22, starting with 5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8836) (1.28 g, 4.3 mmol); dimethylformamide diacetal (4 ml, 21.9 mmol); trifluoroacetic acid (12.5 ml, 83 mmol); sodium cyanoborohydride (4.1 g, 65 mmol); 90°C for 8 hours.
EXAMPLE 33 -Bis(chloroethylamino-2-ethyl)amino-9-fl-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8841) Compound CRL 8841 is prepared according to the 10 procedure described in Example 24, starting with 5-amino-9-H-quino[4, 3, 2-de] [1,7]phenanthrolin-9-one (CRL 8836) (1 g, 3.95 mmol); chloroacetaldehyde (2.6 ml, 16.8 mmol); acetic acid (30 ml); sodium cyanoborohydride (0.63 g, 10 mmol); 30 minutes at room 15 temperature.
EXAMPLE 34 -(Chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de]-[1,7]phenanthrolin-9-one (CRL 8842) Compound CRL 8842 is also obtained during the procedure described in the above example from 5-amino-9-H-quino-[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8836).
EXAMPLE 35 4-Bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8843) Compound CRL 8843 is prepared according to the procedure described in Example 27, starting with 5-amino-9-H-quino[4,3,2-de] [1,7]phenanthrolin-9-one 30 (CRL 8836) (0.6 g, 2.01 mmol); 24 ml of acetic acid; bromine (35 (0.1, 0.67 mmol); 50°C for 6 hours.
EXAMPLE 36 7-Nitro-9-fl-quino[4,3,2-de][1,7]phenanthrolin-9-one 35 (CRL 8838) Compound CRL 8838 is prepared according to the procedure described in Example 6, starting with 9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8529) (1 g, 3.53 mmol); 23 ml of sulfuric acid and 23 ml of nitric acid; 130°C for 2 hours.
EXAMPLE 37 7-Amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8837) Compound CRL 8837 is prepared according to the procedure described in Example 7, starting with 7-nitro-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one 10 (CRL 8838) (0.2 g, 0.61 mmol); iron (0.19 g, 3.38 mmol), 10 ml of acetic acid/water mixture (50/50).
EXAMPLE 38 12-Methoxy-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8844) Compound CRL 8844 is prepared according to the procedure described in Example 2 9, starting with 3-methoxy-6-methyl-l,ll-diazanaphthacene-5,12-dione 20 (Intermediate D2) (0.76 g, 25 mmol); dimethylformamide diacetal (2 ml, 11.67 mmol); 120°C for 30 minutes; NH4CI (4.5 g); 500 ml of ethanol; refluxed for 30 minutes.
The results of the pharmacological tests, presented below, demonstrate the cytotoxic qualities of the compounds of formulae I and la, and also the maximum tolerated doses. These data enable the therapeutic value of the claimed compounds to be assessed. 1 - Determination of the maximum tolerated dose (MTD) The evaluation of the maximum tolerated dose was 35 performed on 4- to 6-week-old B6D2Fl/Jico mice. The compounds were administered intraperitoneally at increasing doses ranging from 2.5 to 160 mg/kg. The value of the MTD (expressed in mg/kg) is determined from the observation of the survival rate of the animals over a 14-day period after a single administration of the products under consideration. The change in the weight of the animals is also monitored during this period. When the value of the MTD is 5 greater than 160 mg/kg, the value of the MTD is considered as 160 mg/kg by default.
The results of the estimation of the maximum tolerated dose (MTD) are collated in Table I below: - 48 -TABLE I Compounds CRL MTD (mg/kg) CRL 8274 (Ascididemin) CRL 8269 (2-bromoleptoclinidone) 40 CRL 8323 (Example 1) CRL 8301 (Example 2) > 160 CRL 8241 (Example 3) > 160 CRL 8325 (Example 4) > 160 CRL 8297 (Example 5) > 160 CRL 828 9 (Example 6) CRL 8344 (Example 7) > 160 CRL 8248 (Example 8) > 160 CRL 8347 (Example 9) > 160 CRL 8292 (Example 13) > 160 CRL 8290 (Example 12) 80 CRL 8333 (Example 14) > 160 CRL 8368 (Example 10) > 160 CRL 8369 (Example 15) > 160 CRL 8373 (Example 16) > 160 CRL 8387 (Example 11) > 160 CRL 8389 (Example 17) > 160 CRL 84 06 (Example 19) > 160 CRL 84 07 (Example 20) > 160 CRL 8416 (Example 21) > 160 CRL 8419 (Example 22) 40 CRL 8418 (Example 23) 40 CRL 8422 (Example 24) > 160 CRL 8423 (Example 25) > 160 The majority of the products described in the family of 5 ascididemin or of its isomer do not show any direct toxicity (MTD >160 mg/kg) and may thus be used in vivo at high tissue concentrations, and thus at high doses. 2 - Cytotoxic activity on tumor cell lines in culture The influence of the compounds of formulae I and la on neoplastic cells was evaluated using the MTT 5 colorimetric test. The principle of the MTT test is based on the mitochondrial reduction by metabolically active live cells of the yellow product MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into a blue product, formazan. The amount of formazan 10 thus obtained is directly proportional to the amount of live cells present in the culture well(s). This amount of formazan is measured by spectrophotometry.
The cell lines are maintained as a monolayer culture at 15 37°C in closed culture dishes containing MEM 25 MM HEPES base medium (minimum essential medium). This medium, adapted to the growth of a varied range of mammalian diploid or primary cells, is then supplemented: - with an amount of 5% FCS (Fetal Calf Serum) decomplemented at 56°C for 1 hour, - with 0.6 mg/ml of L-glutamine, - with 200 IU/ml of penicillin, - with 200 mg/ml of streptomycin, - with 0.1 mg/ml of gentamycin.
The 12 human cancer cell lines used were obtained from the American Type Culture Collection (ATCC, Rockville, 30 MD, USA). These 12 cell lines are: - U-373MG (code ATCC: HTB-17) and U-87MG (code ATCC: HTB-14) which are two glioblastomas, - SW1088 (code ATCC: HTB-12) which is an 35 astrocytoma, - A549 (code ATCC: CCL-185) and A-427 (code ATCC: HTB-53) which are two non-small-cell lung cancers, HCT-15 (code ATCC: CCL-225) and LoVo (code ATCC: CCL-229) which are two colorectal cancers, T-47D (code ATCC: HTB-133) and MCF7 (code ATCC: HTB-22) which are two breast cancers, J82 (code ATCC: HTB-1) and T24 (code ATCC: HTB- 4) which are two bladder cancers, PC-3 (code ATCC: CRL-1435) which is a prostate cancer.
Experimentally: 100 fxl of a cell suspension containing 20 000 to 50 000 (depending on the cell type used) cells/mL of culture medium are inoculated in flat-bottomed 96-well multi-well plates and are incubated at 15 37 °C under an atmosphere comprising 5% C02 and 70% humidity. After incubating for 24 hours, the culture medium is replaced with 100 (ill of fresh medium containing either the various test compounds at concentrations ranging from 10"5 to 10"10 M or the 20 solvent used to dissolve the test products (control condition). After incubating for 72 hours under the above conditions, the culture medium is replaced with 100 fil of a yellowish solution of MTT dissolved at a rate of 1 mg/mL in RPMI 1640. The microplates are 25 reincubated for 3 hours at 37 °C and then centrifuged for 10 minutes at 400 g. The yellowish solution of MTT is removed and the blue formazan crystals formed at the cellular level are dissolved in 100 fil of DMSO. The microplates are then agitated for 5 minutes. The 30 intensity of the resulting blue coloration, and thus of the conversion of the yellow MTT product into blue formazan by the cells that are still alive at the end of the experiment is quantified by spectrophotometry using a Dynatech Immunoassay System machine at 35 wavelengths of 570 nm and 630 nm corresponding, respectively, to the maximum absorption wavelengths of formazan and to the background noise. Software built into the spectrophotometer calculates the average optical density values and also the standard deviation (Std. Dev.) and standard error of mean (SEM) values.
The inhibitory activity on the cell growth of the 5 compounds of formulae I and la on the different tumor cell lines was compared with that of the natural product ascididemin (CRL 8274) . All of the compounds show significant inhibitory activity on the cell proliferation of the 12 human tumor lines: U-87MG, U-10 373MG, SW 1088, T24, J82, HCT-15, LoVo, MCF7, T-47D, A549, A-427 and PC-3 with a 50% inhibitory concentration (IC50) which is between 10~6M and 10"10M, depending on the compounds and the tumor lines tested. By way of example, the values of the concentrations 15 flanking the IC50 values which are obtained on the various cell lines are given in Table II: TABLE II COMPOUNDS CELL LINES CRL U-87MC 0-373MG SW1088 T24 J82 IICT-15 LoVo MCF7 T-47D A549 A-427 PC-3 CRL8274 lio'.io'i lio'.io'i |10',I0'| lio'.io'i lio'.io'i IIO-'.IO-'l IIO-'.IO-'l IIO-'.IO-'l IIO^IO-'l |I06,I0'| lio'.io'i |10',10*| CRL8289 no'.io'i |I0',10'| |IOJ,IO'| Ito'.io'l |10'',10'| lio'.io'i lio'.io'i lio'.io'i |IO',IO'| IIO-'.IO-'l lio'.io'i |lfl'.10-'l CRL8248 lio'.io'i |I0', I0'| no'.io'i |IO',IO'| [lo'.io'l 110',10'| lio'.io'i lio'.io'i Ito'.io'l lio'.io'i lio'.io'i lio'.io'i CR 1,8241 lio'.io'i |I0',I0'| lio'.io'i no'.io'i |10',I0"'| lio'.io'i IIO-'.IO-'l lio'.io'i IIO'.IO-'l lio'.io'i lio'.io'i lio'.io'i CRL8297 lio'.io'i lio'.io'i |10*,I0'| lio'.io'i IIO-'.IO-'l IIO'.IO-'l IIO-'.IO-'l lio'.io'i lio'.io'i |lo',lo'| lio'.io'i |lo',ll»-'| CRI.B301 |10',I0'| lio'.io'i |I0',I0'| lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i IIO'.IO-'l IIO-'.IO-'l CRLB323 lio'.io'i |I0',I0"| lio'.io'i |I0',I0'| no'.io'i lio'.io'i lio'.io'i lio'.io'i IIO-'.IO-'l lio'.io'i lio'.io'i IIO-'.IO-'l CR1.8325 lio'.io'i lio'.io'i |10',l0'| lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i CRL8344 lio'.io'i |10',I0'| |I0',104| |I0',I0J| |I0',10'| IIO-'.IO-'l IIO'.IO-'l lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i CRL8J47 |I0',I0J| lio'.io'i Ito'.io-'l |I0',I0'| IIO-'.IO-'l IIO'.IO-'l |I0',I0'| lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i CRI.8368 lio'.io'i |io',io-'| |I0'*,10"*| IIO^IO'l lio'.lfl'l lio'.io'i |I0',I0'| IIO-'.IO-'l lio'.io'i lio'.io'i lio'.io'i |10"* I0"'| CRI.8369 |I05,1«'| |I0',10') |IO',IO'| lio'.io'i IIO-'.IO-'l lio"*, IO'I |I0',I0'| IIO-'.IO-'l lio'.io'i iio'.io'i lio'.io'i IIO-'.IO-'l CRL8373 lio'.io'i |I0',10'| IIO-'.IO-'l |10"*,I0"'| |10-*,I0'| lio'.io'i |IO-*,IO-'| lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i CRL8387 |io-5,io-*| |I05.10'| IIO'.lO"*! |I0',I0'| IIO'.IO-'l |I0-',I0"*| |I0',I0''| |I0*.I0'| lio'.io'i lio'.io'i lio'io'i 110*1 CRUI389 lio'.io'i lio'.io'i |'IO"*,IO"'| |I0',I0'| lio'.io'i lio'.io'i IIO-'.IO-'l |IO',IO"'| lio'.io'i lio'.io'i IIO'.IO'I lio'.io'i CR1.8268* lio'.io'i lio'.io'i >10' |IO',IO'l no'.io'i IIO'.IO-'l |10*,10'| lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i CRI.8322* , |I0',I0"'| lio'.io'i >10' >I05 >10'' lio'.io'i >10'' |IO',IO'| lio'.io'i lio'.io'i lio'.io'i >10' CRL8324V lio'.io'i >10'' >10' >io' >10 ' lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i IIO-'.IO-'l CRU422 lio'.io'i lio'.io'i |I0',I0''| lio'.io'i |10',10'| lio'.io'i IIO'.IO-'l lio'.io'i lio'.io'i lio'.io'i lio'.io'i lio'.io'i CRL8423 |lo',lo'| fI0"*.I0"'| |I0-',I0"'| |I0*,10lol IIO-'.IO-'l lio'.io'i |IO',in'| IIO'.IO-'l lio'.io'i IIO'.IO-'l |I0',I0-|C| lio'.io'i Inhibitory concentrations (M) flanking the value of the 50% inhibitory concentration of the compounds of formula I, II(*) or III (**) on the cell lines Table III gives the results of the average IC50 values (in nM) (calculated from the cytotoxic activity on the 12 tumor lines studied) and the MTD/IC50 ratios (these ratios are calculated by forming the ratio of the MTD 5 values and the IC50 values expressed as numbers without units).
TABLE III Compounds CRL IC50 (nM) MTD/IC50 MTD/IC50* CRL 8274 (Ascididemin) 100 0.20 1 CRL 8269 (2-bromoleptoclinidone) 120 0.33 2 CRL 828 9 (Example 6) 2.00 CRL 824 8 (Example 8) 80 2 .00 CRL 8241 (Example 3) 140 1.14 6 CRL 8297 (Example 5) 90 1.78 9 CRL 8325 (Example 4) 37 4 .32 22 CRL 8344 (Example 7) 53 3.02 CRL 8347 (Example 9) 21 7.62 38 CRL 8323 (Example 1) 60 0.33 2 CRL 8301 (Example 2) 270 0.59 3 CRL 8389 (Example 17) 420 0.38 2 CRL 8368 (Example 10) 480 0.33 2 CRL 84 06 (Example 19) 60 2 . 67 13 CRL 8407 (Example 20) 22 7 .27 36 CRL 8416 (Example 21) 80 2.00 CRL 8418 (Example 23) 110 0.37 2 CRL 8419 (Example 22) 60 0.67 3.3 CRL 8422 (Example 24) 100 1. 60 8.3 CRL 8423 (Example 25) 7 22.86 114 *: the ratio MTD/IC50 for the various compounds was estimated by taking as reference a ratio equal to 1 for ascididemin.
The compounds described show, on the tumor cell line 15 models, IC50 values (nM) which are greater than or equivalent to that of ascididemin. With the exception of CRL 8289 (whose maximum tolerated dose is equivalent to that of ascididemin, but whose IC50 value is ten times lower than that of ascididemin), the maximum tolerated doses of the compounds described, considered 5 by default as equivalent to 160 mg/kg, are markedly higher than those of ascididemin (20 mg/kg). These results suggest that this novel family of compounds have no direct toxicity. Consequently, the tolerance/cytotoxic activity ratios of the compounds 10 illustrated in the present invention are markedly higher than that of the natural ascididemin. These compounds may thus be used as antitumor drugs, for their cytotoxic properties, at tissue concentrations that are higher than those induced with the natural 15 ascididemin. They are thus characterized by better therapeutic manageability. CRL 8289, whose IC50 value is 10 nM, also shows better therapeutic manageability than ascididemin.
By virtue of their cytotoxic properties, the compounds of formulae I and la as described, or in the form of acceptable pharmaceutical salts or solvates, may be used as active principles of drugs.
The compounds of formulae I and la are generally administered in dosage units established either per m2 of body surface or per kg of weight. Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed 30 with one (or more) pharmaceutical excipient (s) .
The compounds of formulae I and la may be used, according to the cancer pathology of the individual to be treated, at doses of between 0.05 and 350 mg/m2 of 35 body surface, preferably at doses from 0.5 to 50 mg/m2/day for a curative treatment in the acute phase as a function of the number of treatment cycles of each cure. For maintenance treatment, the compounds of formulae I and la will advantageously be used at doses from 0.05 to 25 mg/m2/day and preferably at doses from 0.1 to 1.5 mg/m2/day depending on the number of treatment cycles of the cure. They may be combined with antitumor drugs used in validated intensive multidrug 5 therapy protocols.
In the pharmaceutical compositions of the present invention for oral or intravenous administration, the active principles may be administered in unit forms of 10 administration, mixed with conventional pharmaceutical supports that are suitable for human therapy. The suitable unit forms of administration comprise oral-route forms such as tablets, which may be splittable, or gel capsules, implants and intravenous 15 administration forms.
For a parenteral administration (intravenous infusion at a constant flow rate), sterile aqueous suspensions, sterile isotonic saline solutions or sterile and 20 injectable solutions which contain pharmacologically compatible dispersants and/or solubilizing agents, for example propylene glycol, polyethylene glycol or a 0-cyclodextrin, are used.
Thus, to prepare an aqueous solution for intravenous injection intended for an infusion performed over 1 to 24 h, it is possible to use a co-solvent: an alcohol such as ethanol, a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such 30 as Tween 80.
When a solid composition in the form of tablets is prepared, a wetting agent such as sodium lauryl sulfate may be added to the micronized or unmicronized active 35 principle, and the whole is mixed with a pharmaceutical vehicle such as silica, gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets may be coated with sucrose, with various polymers or with other suitable materials, or

Claims (1)

  1. - 56 - alternatively they may be treated such that they have sustained or delayed activity and such that they continuously release a predetermined amount of active principle. 5 A preparation as gel capsules is obtained by mixing the active principle with a diluent such as a glycol or a glycerol ester and by incorporating the mixture obtained into soft or hard gel capsules. 10 The active principle may also be formulated in the form of microcapsules or microspheres, optionally with one or more supports or additives. 15 The active principle may also be presented in the form of a complex with a cyclodextrin, for example a-, 0- or y-cyclodextrin, 2-hydroxypropyl-[3-cyclodextrin or methyl-p-cyclodextrin. 20 The compounds of formulae I and la will be used in the treatment of most solid tumors on account of their powerful cytotoxic activities, in particular for treating cerebral tumors, lung cancers, ovarian and breast tumors, colorectal cancers, prostate cancers and 25 testicular tumors. - 57 - CLAIMS A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of general formulae I and la below for treating, by virtue of their cytotoxic properties, cancerous tumors and their metastases: in which: X is chosen from oxygen, an =NH group and an =N-OH group, Ri is chosen from hydrogen, halogens, a nitro group and groups -NR8R9 in which R8 and R9 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (C1-C6) alkoxy groups, a guanidino group, groups -NRioRn in which Ri0 and Ru are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n-Y with Y being chosen from halogens and CN, -CH(0-Et)2/ (Ci-Ce) alkoxy, -0- (CH2) 2~N (CH3) 2 and -N(CH3)2 groups and n = 1 to 3, R4 is chosen from, hydrogen, halogens, nitro groups and groups -NRi2Ri3 in which Ri2 and R13 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: hydrogen or a halogen atom, AMENDED SHEET - 58 - Ci~C6 alkyl, hydroxyl, C1-C6 alkoxy, (Ci-Ce) alkoxy (Ci~Ce) alkyl, (C1-C4) alkylcarbonyloxy-(C1-C4) alkyl, -CHO, -COOH, -CN, -C02Ri4, -CONHR14 and -CONR14R15 groups, -NHCOR14 and -NR14R15 in which R14 and Ri5 are chosen, independently of each other, from hydrogen and (Ci-Cg) alkyl, -phenyl-CO-CH3 and -CH2-CH2-N (CH3)2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3) 2t morpholino, nitro or S03H groups, groups: -CH2-N-COOR15 , -CH2-N-COOR16j i I CH2-COOR17 OH2 —Ar Ri6 and R17 being chosen from C1-C6 alkyl groups and Ar being a C6-C14 aryl group, with the exclusion of the compounds of formula I containing the combination: X = 0, and, either : Ri, R2, R3, R4, R7 = H, or : Ri, R3, R4, R5, R6, R7 = H and R2 = Br, and with the exclusion of the compound formula la containing the combination X = 0 and Ri, R2, R3, R4, R5, R6, R7 = H, and the addition salts of these compounds with pharmaceutically acceptable acids. A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of formula I in which: X is chosen from oxygen, an =NH group and an =N-OH group, Ri is chosen from hydrogen, halogens, a nitro group and groups -NR8R9 in which Rg and R9 AMENDED SHEET - 59 - are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (C1-C6) alkoxy groups, a guanidino group, groups -NRi0Rn in which Ri0 and Ru are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl, -(CH2)2-N(CH3)2, and -(CH2)2-0-(CH2)2-N(CH3)2 groups, R4 is chosen from hydrogen, halogens, nitro groups and groups -NRi2R13 in which Ri2 and Ri3 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: hydrogen or a halogen atom, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, -CHO, -COOH, -CN, -CO2R14, -CONHR14 and -CONR14R15 groups, -NHCOR14 and -NR14R15 groups in which Ri4 and R15 are chosen, independently of each other, from hydrogen and (Ci-C6) alkyl and -CH2-CH2-N (CH3) 2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3)2, morpholino, nitro or S03H groups, groups: -CH2 - N -COOR16 . -CH2- N- COORib , I I CH2-COOR17 CH2-Ar Ri6 and R17 being chosen from Ci-Cg alkyl groups and Ar being a C6-C14 aryl group, with the exclusion of the compounds in which X = 0, and, either : Rlf R2, R3, R4, R5, Rs/ R7 = H, or : Ri, R3, R4, R5, R6, R7 = H and R2 = Br, or Ri, R2f R3/ R4, R6r R7 = H and R5 = OH, and the addition salts of these compounds with pharmaceutically acceptable acids. AMENDED SHEET - 60 - The pharmaceutical composition as claimed in'-, claim 2, comprising an effective amount of a compound chosen from the compounds of formula I in which: X represents oxygen, Ri is chosen from hydrogen and an amino group, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-Ce) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from hydrogen, methyl groups, (C1-C4) phenylalkyl, - (CH2)2-N(CH3)2, - (CH2)2-0-(CH2)2-N(CH3)2 groups, R4 is chosen from hydrogen, halogens and nitro and amino groups, Rs, R6 and R7 represent a hydrogen, with the exclusion of the compounds in which Rl/ R2f ^-3/ R4 r R5 / R6 r ^7 = H, Or Rl, R3/ R-5 r 1^-6 a R7 = H and R2 = Br, and the addition salts of these compounds with pharmaceutically acceptable acids. The pharmaceutical composition as claimed in claim 1, comprising an effective amount of a compound chosen from the compounds of formulae I and la in which: X represents oxygen, Ri is chosen from hydrogen and an amino group, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-Ce) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from hydrogen, methyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n-Y with Y being chosen from halogens and groups CN, -CH(0-Et)2, (C1-C6) alkoxy, -0-(CH2)2-N(CH3)2 and -N(CH3)2 and n = 1 to 3, AMENDED SHEET - 61 - R4 is chosen from hydrogen, halogens, and nitro and amino groups, R5 is chosen from a hydrogen, a halogen and a methoxy group, R6 and R7 are chosen from hydrogen and Ci-C6 alkoxy, (Ci-Ce) alkoxy (Ci-Ce) alkyl and -CH2OCOCH3 groups, with the exclusion of the compounds of formula I in which Ri, R2, R3, R4, R5, R6, R? = h or Ri, R3, R4, R5, R6, R7 = H and R2 = Br, and of the compound of formula la in which Ri, R2, R3, R4, R5, R6 / R7 = H, and the addition salts of these compounds with pharmaceutically acceptable acids. The composition as claimed in claim 4, in which the compounds are chosen from: 5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin- 9-one, 5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenan-throlin-9-one, 5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 7-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 7-nitro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, AMENDED SHEET - 62 - 5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenan-throlin-9-on£, 5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one, 5-bis (2-chloroethyl) amino-9H-qui.no [4,3, 2-de] -[1,10]phenanthrolin-9-one, 5-(2-chloroethyl)amino-9H-quino[4,3,2-de] [1,10]-phenanthrolin-9-one, 12-methoxy-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin- 9-one, 11-acetoxymethyl-9-H-quino[4,3,2-de][1,10]phenanthrolin- 9-one, 5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de] [1,7]phenanthrolin-9-one, 5-bis(chloroethylamino-2-ethyl)amino-9-H-quino-[4,3,2-de][1,7]phenanthrolin-9-one, 5- (chloroethylamino-2-ethyl)amino-9-H-quino[4,3, 2-de] [1,7]phenanthrolin-9-one, 4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin- 9-one, 7-nitro-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 7-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 12-methoxy-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, and the addition salts thereof with pharmaceutically acceptable acids. The use of a compound as defined in one of claims 1 to 5, for the manufacture of an anticancer drug. AMENDED SHEET - 63 - The use as claimed in claim 6, in which the compounds are chosen from: 5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenan-throlin-9-one, 5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin- 9-one, 5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 7-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 7-nitro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenan-throlin-9-one, 5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one, 5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one, 5-(2-chloroethyl)amino-9H~quino[4,3,2-de][1,10]— phenanthrolin-9-one, 12-methoxy-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin- 9-one, 11-acetoxymethyl-9-H-quino[4,3,2-de][1,10]phenanthrolin- 9-one, 5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, AMENDED SHEET - 64 - 5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 5-(dimethylamino-2-ethyl) amino-9-H-quino[4, 3, 2-de] [1,7]phenanthrolin-9-one, 5-bis(chloroethylamino-2-ethyl)amino-9-H-quino-[4,3,2-de][1,7]phenanthrolin-9-one, 5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de] [1,7]phenanthrolin-9-one, 4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenan-throlin-9-one, 7-nitro-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 7-amino-9-H-quino[4,3, 2-de] [1,7]phenanthrolin-9-one, 12-methoxy-9-H-quino[4,3, 2-de] [1,7]phenanthrolin-9-one, and the addition salts thereof with pharmaceutically acceptable acids. Compounds of general formulae I and la Formula I Formula la in which: X is chosen from oxygen, an =NH group and an =N-OH group, Ri is chosen from hydrogen, halogens, a nitro group and groups -NRgRg in which Rs and R9 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-Cg) alkoxy groups, a AMENDED SHEET - 65 - guanidino group, groups -NR10R11 in which Ri0 and Rxx are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (Ci~C4) phenylalkyl groups and groups -(CH2)n_Y with Y being chosen from halogens and CN, -CH(0-Et)2, (Ci-Ce) alkoxy, -0- (CH2) 2-N (CH3) 2 and -N(CH3)2 groups and n = 1 to 3, R4 is chosen from hydrogen, halogens, nitro groups and groups -NR12R13 in which R12 and R13 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: hydrogen or a halogen atom, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, (C1-C6) alkoxy (C1-C6) alkyl, (C1-C4) alkylcarbonyloxy-(Ci-C4) alkyl, -CHO, -C00H, -CN, -C02Ri4, -C0NHRi4 and -CONR14R15 groups, -NHCOR14 and -NR14R15 in which R14 and R15 are chosen, independently of each other, from hydrogen and (Ci-Ce) alkyl, -phenyl-CO-CH3 and -CH2-CH2-N (CH3) 2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3) 2r morpholino, nitro or S03H groups, groups: -CH2 -N -COOR16 , -CH2 - N- COOR16 , i | Chfe-COOR17 Chfe-Ar Ri6 and R17 being chosen from C1-C6 alkyl groups and Ar being a C6-C14 aryl group, with the exclusion of the compounds of formula I in which X = 0, and, either Ri, R2, R3, R4, R5/ R6a R7 = H, or Rx, R3, R4, R5, Re, R7 = H and R2 = Br, or Ri? R2r R41 Rs^ R6/ R7 = H and R3 = OCH3, or Rx, R2, R3, R4, Rer R7 = H and R5 = OH or 0CH3, or Rx = NO2 and R2, R3/ R4/ R5/ R7 =H, and with the exclusion of the compound formula la in which X = 0 and Rx, R2, R3, R4, Rsr R6^ R7 = H, AMENDED SHEET - 66 - and the addition salts of these compounds with pharmaceutically acceptable acids. Compounds as claimed in claim 8, of formula I in which: X is chosen from oxygen, an =NH group and an =N-OH group, Ri is chosen from hydrogen, halogens, a-nitro group and groups -NR8R9 in which Rs and Rg are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Ri0 and Rn are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl, - (CH2) 2-N (CH3) 2r and -(CH2)2-0-(CH2) 2-N (CH3) 2 groups, R4 is chosen from hydrogen, halogens, nitro groups and groups -NR12R13 in which R12 and R13 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: hydrogen or a halogen atom, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, -CHO, -COOH, -CN, -CO2R14, -CONHR14 and -CONRi4R15 groups, -NHC0Ri4 and -NR14R15 in which R14 and R15 are chosen, independently of each other, from hydrogen and (Ci-C6) alkyl and -CH2-CH2-N (CH3) 2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3)2, morpholino, nitro or S03H groups, groups: AMENDED SHEET 67 - -CHj-N_COOR16 , -CHs-N-COOR16, ! | aVCOOR17 CHg-Ar Ri6 and R17 being chosen from C1-C6 alkyl groups and Ar being a C6-C14 aryl group, 5 with the exclusion of the compounds in which X = 0, and, either Rx, R2, R3, R4, R5, R6, R7 = H, or Ri, R3, R4, R5, Rg, R7 = H and R2 = Br, or Ri, R2, R4, R5, Rg, R7 = H and R3 = OCH3, or Rx, R2, R3, R4, 1^6r R7 = H and R5 = OH or OCH3, or Rx = N02 and R2, 10 R3, R4, R5, R6, R7 = H, and the addition salts thereof with pharmaceutically acceptable acids. 10. Compounds as claimed in claim 8, which are: 15 5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin- 9-one, 5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-broitio-9H-quino [4, 3, 2-de] [1,10]phenanthrolin-9-one, 20 7-amino-9H-quino[4,3, 2-de] [1,10]phenanthrolin-9-one, 5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-25 9-one, 5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de][1,10] -phenanthrolin-9-one, 5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]phenan-throlin-9-one, 30 5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]phenan- throlin-9-one, 12-methoxy-9-Jf-quino [4, 3,2-de] [1,10] phenanthrolin-9-one, 4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one, AMENDED SHEET - 68 - 11-acetoxymethy1-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one, 5-bromo-9-H-quino[4,3, 2-de] [1,7]phenanthrolin-9-one, 5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 5 5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de]- [1,7]phenanthrolin-9-one, 5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de] -[1,7]phenanthrolin-9-one, 5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de] -10 [1,7]phenanthrolin-9-one, 4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 7-nitro-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 7-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one, 15 12-methoxy-9-H-quino[4,3, 2-de] [1,7]phenanthrolin-9-one, and the addition salts thereof with pharmaceutically acceptable acids. 11. A process for preparing a compound of formula la, 20 in which: X is chosen from oxygen, an =NH group and an =N-OH group, Ri is chosen from hydrogen, halogens, a nitro group and groups -NRsRg in which R8 and Rg 25 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci~Ce) alkoxy groups, a 30 guanidino group, groups -NR10R11 in which R10 and Rn are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n~Y with Y being chosen from halogens and CN, -CH(0-Et)2^ (Ci-Cg) alkoxy, 35 -0- (CH2) 2~N (CH3) 2 and -N(CH3)2 groups and n = 1 to 3, R4 is chosen from hydrogen, halogens, nitro groups and groups -NR12R13 in which R12 and Ri3 AMENDED SHEET - 69 - are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: hydrogen or a halogen atom, Ci-C6 alkyl, hydroxyl, C1-C6 alkoxy, (Ci-Cg) alkoxy (Ci-Ce) alkyl, (C1-C4) alkylcarbonyloxy-(C1-C4) alkyl, -CHO, -COOH, -CN, -C02Ri4, -CONHR14 and -CONR14R15 groups, -NHCOR14 and -NR14R15 in which R14 and R15 are chosen, independently of each other, from hydrogen and (C1-C6) alkyl, -phenyl-CO-CH3 and -CH2-CH2-N(CH3)2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3)2, morpholino, nitro or S03H groups, groups: -Chfe -N -COOR16 , -CHg- N- COOR16 , CH2-COOR17 CHj—Ar Ri6 and R17 being chosen from C1-C6 alkyl groups and Ar being a C6-C14 aryl group, which consists in: a - condensing a chlorobenzoic acid of formula: with a dimethoxyaniline of formula: AMENDED SHEET - 70 -OMe OMe to give a compound of formula Ila; OMe ^ h ho2c OMe b - cyclizing the compound of formula Ila to give a compound of formula: c - converting the compound into a quinone of formula Ilia: AMENDED SHEET - 71 - d - reacting the quinone of formula Ilia with an azadiene of formula: to give a compound of formula IVa: Rs o CH3 R*;e - reacting the compound of the formula IVa with dimethylformamide diethyl acetal to give the compound, of formula la,;f - and, optionally, converting the compound thus obtained into another compound of formula la.;AMENDED SHEET;- 72 -;12. A use of a pharmaceutical composition defined in claim 1 in the manufacture of a medicament for treating a cancer.;5;13. A process for preparing compounds of general formula I, of formula:;10 in which:;Ri is chosen from hydrogen, halogens, a nitro group and groups -NR8R9 in which R8 and R9 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, 15 - R2 is chosen from hydrogen and halogens,;R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (Ci-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from 20 hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n-Y with Y being chosen from halogens and CN, -CH(0-Et)2, (Ci-Ce) alkoxy, -0- (CH2) 2-N (CH3) 2 groups and -N(CH3)2 and n = 1 to 3,;25 - R4 is chosen from hydrogen, halogens,;nitro groups and groups -NRi2Ri3 in which Ri2 and Ri3 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups,;R5, Rg and R7 are chosen from: 30 hydrogen or a halogen atom,;OFF<rcL PROPE;office OF N.Z.;NOV 2003 REC EIVED;- 73 -;Ci~C6 alkyl, hydroxyl, Ci~Ce alkoxy, (Ci-Cs) alkoxy (Ci~C6) alkyl, (C1-C4) alkylcarbonyloxy-(C1-C4) alkyl, -CHO, -COOH, -CN, -C02Ri4, -CONHRi4 and -CONRi4Ri5 groups, -NHCORi4 and -NR14R15 in which R14 and R15 are chosen, independently of each other, from hydrogen and (Ci-C6) alkyl, -phenyl-CO-CH3 and -CH2-CH2-N (CH3) 2 groups,;-phenyl-CO-CH3 or -phenyl-CO-CH=CH-N(CH3) 2r morpholino, nitro or S03H groups,;groups:;-CH2 ~N-COOR15 , -CHz- N-COOR16, CH2-COOR17 CH2-Ar;Ri6 and R17 being chosen from Ci-C6 alkyl groups and Ar being a C6-Ci4 aryl group,;with the exclusion of the compounds of formula I in which either Ri, R2, R3, R4, R5, R6, R7 = H, or R-l, R3, R4, R5, R6, R7 = H and R2 = Br, or Ri, R2, R4, R5, Rg, R7 = H and R3 = OCH3, or Ri, R2, R3, R4, R6, R7 = H and R5 = OH or OCH3 or Ri = N02 and R2, R3, R4 r R5r R6/ ^7 - H,;which consists a) in reacting a hydroquinone of formula with a compound of formula;AMENDED SHEET;- 74 -;Ri h2n;Rn ch* r4 in the presence of CeCl3, 7H2O and ethanol to give a compound of formula II cho ' b) in converting the compound of formula II into a compound of formula III c) in reacting the compound of the formula III with HC(OC2H5)2N(CH3)2 in DMF at 120°C to form a compound of formula IV AMENDED SHEET - 75 - d) in cyclizing the compound of formula IV to a compound of formula I in the presence of NH4CI and AcOH, 5 e) optionally converting the compound of formula I thus obtained into another compound of formula II. 10 14. A compound of formula N(CH3)2 15 20 25 30 in which: Ri is chosen from hydrogen, halogens, a nitro group and groups -NR8R9 in which R8 and R9 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R2 is chosen from hydrogen and halogens, R3 is chosen from hydrogen, halogens, (C1-C4) alkyl groups, (C1-C6) alkoxy groups, a guanidino group, groups -NR10R11 in which Rio and Rn are chosen, independently of each other, from hydrogen, (C1-C4) alkyl groups, (C1-C4) phenylalkyl groups and groups -(CH2)n_Y with Y being chosen from halogens and CN, -CH(0-Et)2, (Ci-Ce) alkoxy, -0-(CH2) 2~N (CH3) 2 and -N(CH3)2 groups and n = 1 to 3, R4 is chosen from hydrogen, halogens, nitro groups and groups -NRi2Ri3 in which R12 and R13 are chosen, independently of each other, from hydrogen and (C1-C4) alkyl groups, R5, R6 and R7 are chosen from: AMENDED SHEET - 76 - hydrogen or a halogen atom, Ci-Cfi alkyl, hydroxyl, Ci-C6 alkoxy, (C1-C6) alkoxy (Ci~Cg) alkyl, (C1-C4) alkylcarbonyloxy-(C1-C4) alkyl, -CHO, -COOH, -CN, -C02Ri4/ -CONHRu 5 and -CONR14R15 groups, -NHCOR14 and -NR^R^ in which R14 and Ri5 are chosen, independently of each other, from hydrogen and (Ci-C6) alkyl, -phenyl-C0-CH3 and -CH2-CH2-N(CH3)2 groups, -phenyl-CO-CH3 or -phenyl-CO-CH=CH-10 N(CH3)2, morpholino, nitro or SO3H groups, groups: -Chk — N — COOR16 , -CH2 - N - COOR1e , CH2-COORi7 CH^-Ar 15 Ri6 and RX7 being chosen from Ci~C6 alkyl groups and Ar being a C6-C14 aryl group, with the exclusion of compounds in which either r ^2/ ^3f R4/ r 1^7 ~ H, Or RX, R3, R4, R5, Rg, R7 = H and R2 = Br, or Ri, R2, R4, R5, r6, r7 = H and 20 R3 = OCH3, or Ri, R2, R3, R4, Rg, R7 = H and R5 = OH or 0CH3 or Ri = N02- and R2, R3, R4, R5, Rg, R7 = H, and the addition salts of these compounds with pharmaceutically acceptable acids. 15. A pharmaceutical composition according to claim 1 or 2 substantially as herein described with reference to any example thereof. 16. A compound according to claim 8 or 14 substantially as herein described with reference to any example thereof. 17. A process according to claim 11 or 13 substantially as herein described with reference to any example thereof. 2? NOV 2003 18. A use according to claim 6 or 12 substantially as herein described with reference to any example thereof.
NZ516896A 1999-08-13 2000-08-11 Ascididemin derivatives and their therapeutic applications NZ516896A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9910490A FR2797445B1 (en) 1999-08-13 1999-08-13 ASCIDIDEMINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
FR0006652A FR2809399B1 (en) 2000-05-24 2000-05-24 NEW ASCIDIDEMINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
PCT/FR2000/002312 WO2001012631A2 (en) 1999-08-13 2000-08-11 Ascididemin derivatives and their therapeutic applications

Publications (1)

Publication Number Publication Date
NZ516896A true NZ516896A (en) 2004-02-27

Family

ID=26212422

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ516896A NZ516896A (en) 1999-08-13 2000-08-11 Ascididemin derivatives and their therapeutic applications

Country Status (20)

Country Link
EP (1) EP1202992B1 (en)
JP (1) JP2003507381A (en)
CN (1) CN1195754C (en)
AT (1) ATE276256T1 (en)
AU (1) AU779932B2 (en)
BR (1) BR0013249A (en)
CA (1) CA2393965A1 (en)
CZ (1) CZ2002528A3 (en)
DE (1) DE60013849T2 (en)
DK (1) DK1202992T3 (en)
ES (1) ES2228602T3 (en)
HU (1) HUP0202767A3 (en)
IL (1) IL147900A0 (en)
MX (1) MXPA02001512A (en)
NO (1) NO20020668L (en)
NZ (1) NZ516896A (en)
PL (1) PL353453A1 (en)
PT (1) PT1202992E (en)
SK (1) SK1662002A3 (en)
WO (1) WO2001012631A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548486B1 (en) * 2016-12-05 2021-10-27 Merck Patent GmbH Materials for organic electroluminescent devices

Also Published As

Publication number Publication date
EP1202992A2 (en) 2002-05-08
PL353453A1 (en) 2003-11-17
DE60013849D1 (en) 2004-10-21
JP2003507381A (en) 2003-02-25
HUP0202767A2 (en) 2003-01-28
NO20020668L (en) 2002-04-15
DE60013849T2 (en) 2005-02-03
SK1662002A3 (en) 2002-09-10
CZ2002528A3 (en) 2002-05-15
CA2393965A1 (en) 2001-02-22
MXPA02001512A (en) 2002-07-02
WO2001012631A2 (en) 2001-02-22
NO20020668D0 (en) 2002-02-11
AU779932B2 (en) 2005-02-17
EP1202992B1 (en) 2004-09-15
HUP0202767A3 (en) 2003-12-29
CN1373762A (en) 2002-10-09
AU7012400A (en) 2001-03-13
WO2001012631A3 (en) 2001-07-19
ATE276256T1 (en) 2004-10-15
BR0013249A (en) 2002-04-16
CN1195754C (en) 2005-04-06
DK1202992T3 (en) 2005-01-24
IL147900A0 (en) 2002-08-14
ES2228602T3 (en) 2005-04-16
PT1202992E (en) 2004-12-31

Similar Documents

Publication Publication Date Title
Wall et al. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs
CN113248524B (en) Bisindole alkaloid compound and synthesis method and application thereof
AU7182500A (en) New dihydrofuro (3,4-b) quinolin-1-one compounds, a process for their preparation and pharmaceutical compositions containing them
NZ516896A (en) Ascididemin derivatives and their therapeutic applications
AU2004222044B2 (en) 7-imino derivatives of camptothecin having antitumor activity
AU777689B2 (en) Phenanthroline-7-one derivatives and their therapeutic uses
NZ537015A (en) Anti-tumour polycyclic carboxamides with cytotoxicity
US6583150B1 (en) Pharmaceutical composition based on polyaromatic compounds
CA2936874A1 (en) Water soluble 4-azapodophyllotoxin analogs
EP3596054A1 (en) 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments
MXPA01009322A (en) Pharmaceutical composition based on polyaromatic compounds
ZA200200840B (en) Ascididemin derivatives and their therapeutic applications.
WO2013107278A1 (en) New-type anti-cancer compounds synthesized from reaction of ketone and indole derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)